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II. Abbreviations 
 
APC   antigen-presenting cell 
ASL   airway surface liquid 
BAL   bronchoalveolar lavage 
CF   cystic fibrosis 
CFTR   cystic fibrosis transmembrane conductance regulator 
Cftr-/-   Cftrtm1Unc* Tg(FABPCFTR)1Jaw/J 
CMP   common myeloid progenitor 
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FABP1  fatty acid binding protein1 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
G-MDSC  granulocytic/ neutrophilic myeloid-derived suppressor cell 
GR-1   myeloid differentiation antigen GR-1 
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NO   nitric oxide 
PAMP   pathogen-associated molecular pattern 
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PMN   neutrophil granulocyte 
P. aeruginosa Pseudomonas aeruginosa 
ROS   reactive oxygen species 
SCF   stem-cell factor 
TCR   T-cell receptor 
Th   T helper cell 
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III. Summary 
Tumor associated myeloid suppressive cells have been described in the scientific 
field about 30 years ago. In the year 2007 these cells were given the name myeloid-
derived suppressor cells (MDSCs) due to their myeloid origin and their 
immunosuppressive potential. MDSCs are commonly found in cancer patients, where 
they are known to impair the patients’ immune response leading to severe tumor 
progression. Besides cancer, MDSCs are likewise found to be recruited in 
inflammatory and infectious diseases, where their role is often discussed. According 
to the disease type and/ or the pathogen involved they can be either beneficial or 
detrimental for patients. 
Cystic Fibrosis (CF) is a monogenetic disease caused by mutations in the gene 
encoding for the chloride channel Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR). Morbidity and mortality of CF patients is mainly due to a steady 
decline in the lung function, caused by infections and hyperinflammatory immune 
responses leading to lung injury. Pseudomonas (P) aeruginosa, a gram-negative 
flagellated opportunistic pathogen, is the most common pathogen causing chronic 
infections and leading to severe problems in CF patients. Previous studies from our 
group revealed that MDSC numbers are increased in CF patients, especially in 
patients with chronic P. aeruginosa infections. Among patients with chronic P. 
aeruginosa infections, the amount of MDSCs positively correlated with better lung 
function. 
In this study we investigated the interaction of P. aeruginosa and MDSCs as well as 
assessed the impact of CFTR deficiency. Therefore we performed in vivo acute 
pulmonary infections in wildtype as well as in Cftr-/- mice followed by flow cytometry 
(FACS) analysis to quantify MDSCs in different tissues. We could demonstrate that 
acute pulmonary P. aeruginosa infections potently induce CD11b+Ly6G+Ly6Clow cells. 
These markers describe the profile of granulocytic/ neutrophilic MDSCs (G-MDSCs). 
In vitro expansion of wildtype or Cftr-/- splenocytes with granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6) also resulted in the 
induction of CD11b+Ly6G+Ly6Clow cells. To check for their suppressive nature and 
thereby distinguish the induced CD11b+Ly6G+Ly6Clow cells from neutrophil 
granulocytes, we isolated the cells and assessed their suppressive capability using 
CFSE based T cell suppression assays. The isolated CD11b+Ly6G+Ly6Clow cells 
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from lungs, spleens, bone marrow and bronchoalveolar lavage (BAL) of infected mice 
potently suppressed T cell proliferation ex vivo in a dose-dependent manner, which 
provided evidence that they are G-MDSCs. Intriguingly, the suppressive capability of 
G-MDSCs isolated from lungs, spleens or bone marrow of P. aeruginosa infected 
mice was potently enhanced on cellular basis when compared to G-MDSCs isolated 
from control mice. Contrarily, G-MDSCs isolated from in vitro expanded Cftr-/- 
splenocytes were less suppressive than G-MDSCs isolated from in vitro expanded 
wildtype splenocytes, implying a potential role of CFTR on G-MDSC suppression. 
Altogether, we could demonstrate, that CFTR deficiency seems to hamper G-
MDSCs’ suppressive potential, whereas pulmonary P. aeruginosa airway infection 
induces G-MDSCs and enhances their suppressive capability, and thereby define a 
mechanism by which P. aerugionsa undermines host immunity in vivo. The pathways 
and mechanisms still need to be elucidated. 
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IV. Zusammenfassung 
Tumor-assoziierte myeloische suppressive Zellen wurden vor ca. 30 Jahren 
beschrieben. Im Jahre 2007 wurden diese Zellen aufgrund ihrer myeloischen 
Herkunft und ihrem immunsuppressiven Potential myeloische Suppressorzellen 
(MDSC) genannt. MDSCs kommen häufig in erhöhter Anzahl in Tumorpatienten vor. 
Sie sind bekannt dafür, die Immunantwort des Patienten zu hemmen und 
ermöglichen somit verstärkte Tumorprogression. Neben Krebserkrankungen treten 
MDSCs auch in inflammatorischen und infektiösen Krankheiten auf, wobei ihre Rolle 
oft kontrovers Diskutiert wird. Abhängig von der Erkrankung und/ oder involvierten 
Pathogenen können MDSCs entweder gut, oder schlecht für den Patienten sein. 
Zystische Fibrose (CF) ist eine monogenetische Erkrankung die durch Mutationen im 
Gen das für den Chloridionenkanal Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) kodiert. Die Morbidität und Mortalität der CF Patienten ist 
hauptsächlich auf den Funktionsverlust der Lunge zurückzuführen, die durch 
Infektionen und hyperinflammatorische Immunantworten beschädigt wird. 
Pseudomonas aeruginosa, ein gram-negativer flagellierter opportunistischer Erreger, 
sorgt bei CF Patienten häufig für Infektionen und kann dabei auch zu chronischen 
Infektionen führen und somit großen Schaden in der Lunge anrichten. 
Vorhergehende Studien unserer Arbeitsgruppe wiesen auf, dass MDSCs bei CF 
Patienten in erhöhtem Maße vorkommen, besonders bei CF Patienten mit 
chronischen P. aeruginosa Infektionen. Unter den Patienten mit chronischen P. 
aeruginosa Infektionen korrelierte dabei die Menge an MDSCs positiv mit der 
Lungenfunktion der Patienten. 
In dieser Studie untersuchten wir die Interaktion von P. aeruginosa mit MDSCs und 
ermittelten den Einfluss von CFTR Defizienz. Dazu führten wir in vivo akute 
pulmonäre Infektionen in Wildtyp als auch in Cftr-/- Mäusen durch und quantifizierten 
MDSCs in verschiedenen Geweben mittels Durchflusszytometrie (FACS). Dabei 
fanden wir heraus, dass akute pulmonäre P. aerugionosa Infektionen 
CD11b+Ly6G+Ly6Clow Zellen induzieren, welche zu dem Profil von granulozytären/ 
neutrophilen MDSCs (G-MDSCs) passen. In vitro expansion von Wildtyp oder Cftr-/- 
Splenozyten mit granulocyte-macrophage colony-stimulating factor (GM-CSF) und 
Interleukin-6 (IL-6) induzierte ebenfalls CD11b+Ly6G+Ly6Clow Zellen.  
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Um die suppressive Natur der induzierten CD11b+Ly6G+Ly6Clow Zellen zu 
untersuchen und sie somit von Neutrophilen Granulozyten zu unterscheiden 
isolierten wir sie und evaluierten ihre suppressiven Fähigkeiten mittels CFSE 
basierten T-Zell-Suppressionsversuchen. Die isolierten induzierten 
CD11b+Ly6G+Ly6Clow aus Lungen, Milzen, Knochenmark und bronchoalveolären 
Lavage (BAL) von infizierten Tieren waren in der Lage T-Zell Proliferation 
dosisabhängig stark zu inhibieren, womit wir aufweisen konnten, dass es sich bei den 
induzierten Zellen um G-MDSCs handelt. Interessanterweise war die suppressive 
Fähigkeit der G-MDSCs, die von Lungen, Milzen und Knochenmark von P. 
aeruginosa infizierten Mäusen isoliert wurden auf zellulärer Ebene verglichen mit G-
MDSCs aus Kontrollmäusen verstärkt. Im Gegenzug dazu sind G-MDSCs, die von in 
vitro expandierten Cftr-/- Splenozyten isoliert wurden weniger suppressiv als G-
MDSCs die von in vitro expandierten Wildtyp Splenozyten isoliert wurden, was eine 
potentielle Rolle von CFTR auf die Suppressivität von G-MDSCs vermuten lässt. 
Insgesamt konnten wir zeigen, dass pulmonäre P. aeruginosa Infektionen G-MDSCs 
induzieren und sie in ihrer suppressiven Fähigkeit verstärken und somit konnten wir 
einen Mechanismus aufweisen, mit welchen P. aeruginosa in vivo die Immunantwort 
untergräbt, während CFTR Defizienz die G-MDSC suppressive Fähigkeit in vitro 
abschwächt. Die involvierten Signalwege und Mechanismen, die hierbei involviert 
sind müssen, noch bestimmt werden. 
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1. Introduction 
1.1 The immune system 
The immune system is a complex system consisting of physical and chemical 
barriers, various specific cells and a plethora of soluble components. Altogether, it is 
the defense mechanism of the body to fight against pathogens and malignant tumor 
cells and to maintain cellular homeostasis. It splits into two main branches, the innate 
and the adaptive immune system. The innate immune system consists of 
antimicrobial agents like the complement system or defensins, and innate immune 
cells. Among these are monocytes, neutrophil granulocytes (PMN) and dendritic 
cells, which are also called phagocytes, because of their ability to phagocytose 
pathogens. They recognize conserved molecular structures on pathogens via toll-like 
receptors. After recognition of the so called pathogen-associated molecular patterns 
like lipopolysaccharide or flagellin, the innate immune cells get activated and are able 
to eliminate pathogens and produce a specific set of cytokines and chemokines. 
Cytokines are soluble mediators between cells that are recognized and induce 
specific intracellular mechanisms further activating the immune response; 
chemokines are soluble mediators that lead other immune cells to the site of 
inflammation (1-6). Phagocytes have furthermore the ability to activate the adaptive 
immune response. They process the phagocytosed pathogens into small parts, called 
antigens, and present them on their surface via major histocompatibility complex 
(MHC) molecules to the main initiators of the adaptive immunity, the T cells. CD8+ T 
cells, also called cytotoxic T cells, recognize endogenous antigens on MHC class I 
(MHC-I) molecules while CD4+ T cells, also called T helper cells (Ths), recognize 
exogenous antigens on MHC class II (MHC-II) molecules via their T-cell receptor 
(TCR). T cells have very specialized TCRs that only bind specific antigens. Upon 
recognition of the MHC-II molecule with the presented antigen and receiving a 
secondary costimulatory signal from APCs, naïve Ths are activated, produce high 
amounts of cytokines and start clonal proliferation and differentiation into effector T-
lymphocytes (1). 
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1.1.1 T cell subtypes 
Depending on the cytokine milieu, naïve Ths are differentiating into different subtypes 
of T-helper cells as the main ones being Th1, Th2, Th17 and T cell suppressive 
regulatory T cells (Tregs).  
Th1 cells activate cellular immune responses by activating macrophages and 
cytotoxic T cells. Th2 cells activate humoral immune responses by activating B cells 
that turn into plasma cells and produce high amounts of antibodies. These bind 
specifically to foreign structures like recognized antigens on pathogens, neutralizing 
them and simplifying phagocytosis of these pathogens (1, 7-11). Th17 cells are 
contributing to pathogen elimination at mucosal surfaces, but are also associated 
with autoimmunity and autoinflammation (12). Tregs are the main suppressive cells 
counteracting pro-inflammatory T cell activation and act as an intrinsic way to stop 
overshooting inflammatory T-cell responses (13). 
As T cells are important to mediate and enhance immune responses, unbalanced 
activation of T cells can cause severe damage to the host leading to autoimmune 
diseases and hyper-inflammation (14-18). 
1.2 MDSCs 
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid 
cells that are potently able to suppress T cells. Initially MDSCs have been described 
in cancer patients (19-22) and tumor-bearing mice. More recently MDSCs were also 
found in infectious and autoinflammatory disease conditions like inflammatory bowel 
disease (23), rheumatoid arthritis (24, 25), polymicrobial sepsis (26) and cystic 
fibrosis (27). In cancer, MDSCs are viewed as pathologically induced cells that help 
the tumor cells to evade immune responses by suppressing T-cell responses. 
Increased amounts of MDSCs in cancer patients correlate with a worse survival and 
higher metastatic burden (22). In infectious and autoinflammatory diseases it is 
speculated that MDSCs are induced as physiological immune regulators, but their 
role is controversially discussed and needs further understanding. 
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1.2.1 MDSC origin and expansion 
Figure 1 MDSC homeostasis 
Adapted from Gabrilovich et al. 2009 © Nature publishing group 
Immature myeloid cells (IMCs) are the basis of myeloid innate immune cells like 
granulocytes, dendritic cells and macrophages. They differentiate from common myeloid 
progenitor (CMP) cells, which are derived from haematopoietic stem cells (HSCs). This 
process is controlled by soluble factors like granulocyte/macrophage colony-stimulating 
factor (GM-CSF), stem-cell factor (SCF), macrophage colony-stimulating factor (M-CSF) and 
many others as well as cell-bound molecules (not shown). Under normal conditions, 
immature myeloid cells migrate to peripheral organs, where they differentiate into 
granulocytes, dendritic cells and macrophages. Under pathologic conditions however, 
soluble factors produced by tumors, pathogens or (auto-) inflammatory responses recruit 
immature myeloid cells, leading to an accumulation and activation of the cells and inhibit their 
further differentiation. These cells have the ability to potently suppress immune responses, 
especially T cells and are therefore named myeloid-derived suppressor cells (MDSCs) (28). 
 
In the bone marrow of healthy individuals, hematopoietic stem cells differentiate into 
common myeloid progenitor cells, which in turn differentiate into immature myeloid 
cells (IMCs). These migrate out of the bone marrow and further differentiate into 
mature myeloid cells like macrophages, dendritic cells and granulocytes. This 
differentiation and recruitment is directed by a series of soluble factors like 
granulocyte-macrophage colony-stimulating factor (GM-CSF), stem-cell factor (SCF), 
macrophage colony-stimulating factor (M-CSF) and others. In pathological conditions 
IMCs are recruited to sites of infection, trauma or tumor, where their expansion is 
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promoted whereas their differentiation into mature myeloid cells is blocked and their 
suppressive phenotype is activated by soluble factors like GM-CSF, other cytokines 
(IL-1β, IL-6, IL-10) or bacterial PAMPs (LPS and flagellin) produced by tumor cells, 
bacteria or cells mediating inflammatory responses (28). 
1.2.2 MDSC function 
MDSCs are most commonly known for their ability to suppress T-cell responses via 
direct suppression or the induction of Tregs (29). The suppression of T cells requires 
direct cell to cell contact, thus indicating that MDSCs act through receptors on the cell 
surface or through soluble short-lived molecules (28). Several mechanisms have 
been described to be involved in the suppressive activity of MDSCs. 
Inducing and releasing high amounts of reactive oxygen species (ROS) like 
superoxide anions and hydrogen peroxide is one of the main characteristics related 
to MDSC suppression by causing oxidative stress. In T cells ROS suppress various 
signaling pathways and IL-2 production (30) negatively affecting T-cell signaling, 
activation and proliferation (31). Another mechanism is the metabolism of L-arginine, 
a non-essential amino acid, by inducing the enzymes arginase1 (Arg1) and inducible 
nitric oxide synthase (iNOS) leading to a shortage of L-arginine in the 
microenvironment. T cells are unable to synthesize L-arginine and thereby have a 
diminished proliferation (19, 32). iNOS also produces nitric oxide (NO), that is 
involved in T cell suppression via inhibition of transcription factors (33), MHC-II 
expression (34) as well as induction of apoptosis, leading to cell death (35). NO also 
reacts with superoxide anions to form peroxynitrite, a very powerful oxidant inducing 
nitration and nitrosylation of sulfur-containing amino acids (36). High amounts of 
peroxynitrite have been described to correlate with T-cell unresponsiveness (37) and 
direct contact of MDSCs with T cells lead to nitration of the T-cell receptor and CD8 
molecules, disrupting antigen-specific stimulation of T cells (38). MDSCs are also 
known to modulate the activity and function of other myeloid cells (39) for example by 
releasing IL-10 MDSCs suppress pro-inflammatory IL-12 responses by macrophages 
and DCs decreasing their potential to activate T cells (40). 
 The induction of regulatory T cells (Tregs) by MDSCs has also been described (41, 
42), but is controversially discussed (43) and requires further investigation. 
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1.2.3 MDSC subtypes 
MDSCs are a phenotypically heterogeneous group of myeloid cells, which can be 
grouped into two subtypes, granulocytic MDSCs (G-MDSCs), which resemble 
granulocytes, and monocytic MDSCs (M-MDSCs), which resemble monocytes. G-
MDSCs are the predominant subset in most diseases (44, 45) and produce high 
amounts of ROS but little amounts of NO, while M-MDSCs produce high amounts of 
NO and low amounts of ROS. Both subsets have elevated Arg1 activity (43, 44). 
 
Figure 2 MDSC function and subtypes 
Adapted from Gabrilovich et al. 2009 © Nature publishing group 
MDSCs divide into two subtypes, granulocytic MDSCs (G-MDSCs) and monocytic MDSCs 
(M-MDSCs). While both groups potently suppress T cells, they use different mechanisms. 
While Stat3 activation in G-MDSCs leads to high levels of NADPH and therefore inducing 
high amounts of reactive oxygen species (ROS), Stat1 activation in M-MDSCs leads to high 
levels of inducible nitric oxide synthase (iNOS) and nitric oxide (NO). Both populations share 
high arginase1 (Arg1) activity which further increases their suppressive potential. Commonly 
used markers are for murine G-MDSCs CD11b+Ly6G+Ly6Clow and for human G-MDSCs 
CD11b+CD33+CD66b+. For murine M-MDSCs the markers CD11b+Ly6G-Ly6C+ are 
commonly used and for human M-MDSCs CD11b+CD33+CD14+ respectively (28). 
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Due to their heterogeneity there is no definite way of labeling MDSCs, but commonly 
used markers in human studies are CD33 and CD11b as myeloid cell markers and in 
particular CD66b or CD15 as marker for G-MDSCs whereas CD14 as marker for M-
MDSCs. Additionally missing or less expressed markers HLA-DR– or F4/80– might be 
used to be able to distinguish MDSCs from granulocytes or monocytes respectively 
(43). For mouse studies the myeloid marker CD11b is used, as well as the myeloid 
differentiation antigen GR-1 (GR-1), that is including the granulocyte marker Ly6G 
and the macrophage marker Ly6C. G-MDSCs are specified as CD11b+Ly6G+Ly6Clow 
and for M-MDSCs as CD11b+Ly6G-Ly6C+ (44). These markers are shared with 
granulocytes and macrophages, making it difficult to clearly distinguish MDSCs from 
their mature myeloid “siblings”. Therefore to safely identify MDSC populations, their 
suppressive potential has to be evaluated.  
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1.3 Cystic fibrosis 
Cystic fibrosis (CF) has first been characterized in 1938 and is the most common 
lethal inherited disease in the Caucasian population. While in the first years of 
discovery life expectancy was only a few months due to meconium ileus and 
pancreatic malabsorption (46) nowadays life expectancy has increased to more than 
40 years (47, 48) by enzyme replacement therapy, correcting nutritional defects, 
airway clearance therapies and aggressive treatment against pathogens (49-51) with 
progressive airway disease being the main cause of mortality (52). 
1.3.1 CF pathogenesis 
CF is caused by gene defects in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene, which is encoding for a cAMP-dependent chloride ion 
channel (53, 54). More than 2000 mutations have been found to cause CF, with the 
∆F508 mutation being the most common one. Dysfunctional or lacking CFTR protein 
leads to deregulated ion fluxes, especially leading to hyper-reabsorption of Na+ by 
the epithelial sodium channel (ENaC), causing dehydration of the airway surface 
liquid (50, 55). This in turn hampers ciliary movement and causes thick mucus stasis 
in CF airways that reduces the ability to clear pathogens from the airways (56, 57). 
Besides these physiochemical disturbances in the airways it is also speculated that 
CFTR deficiency intrinsically leads to a hyper-inflammatory condition, for example via 
accumulation of ceramides, which further promotes lung injury (50, 58-60). 
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Figure 3 Effects of CFTR dysfunction: 
Adapted from J Stuart Elborn 2016 © The Lancet 
Disrupted anion transport and absent regulation of the epithelial sodium channel (ENaC) 
leads to mucus abnormalities and reduced airway surface liquid (ASL) hydration, hampering 
the mucociliary clearance. In combination with disrupted interactions with the inflammasome 
and impaired innate immunity this leads to poor pathogen clearance allowing chronic 
infections, a hyper-inflammatory state and therefore causing severe lung injury (52). 
 
The abundance of pathogens and the general inflammatory condition leads to severe 
tissue damage and bronchiectasis via secretion of elastase, cathepsin S and matrix 
metalloproteinases by neutrophils (61-64). While in the early years of disease 
progression pathogens like Haemophilus influenza and Staphylococcus aureus are 
mainly responsible for infections, in the later years, as the epithelial cell integrity is 
disrupted, opportunistic gram-negative bacteria like Pseudomonas aeruginosa and 
fungi like Aspergillus fumigatus take over (58, 65-67). Recent publications point out 
that CF patients suffer from unopposed Th2/Th17 driven T-cell responses, which 
further fuel the hyper-inflammatory state (68-70) and precede P. aeruginosa 
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infections (69). Fitting to these findings previous work from our group also 
demonstrated that Tregs, normally able to counteract the Th2/Th17 driven 
inflammation are diminished in CF patients, especially in patients with chronic P. 
aeruginosa infections (71). 
1.3.2 Treatment of CF 
Treatment of CF includes pancreatic enzyme replacement and nutritional monitoring 
(72-74), prevention and treatment of infections using oral, inhaled and intravenous 
applied antibiotics (75, 76) as well as clearance of airways (75, 77).  
More innovative therapies target the reconstitution of the CFTR protein either by 
usage of small molecules or gene therapy. While for some mutations the small 
molecule ivacaftor has shown to improve CF patients’ constitution, however the effect 
on the most common F508del mutation was rather minor (78-80). Restoration of 
CFTR on a genetic base has recently been reported to have beneficial effects (81). In 
general, these studies suggest that CFTR function can be restored, but further 
studies are needed to increase the efficiency (82). 
All of these therapies are delaying disease progression and respiratory failure, but 
cannot fully prevent it, and therefore in the long run lung transplantation will be 
needed, alluding the need for new therapeutic approaches. 
1.3.3 CF mouse model  
Ever since the murine Cftr gene has been described 1991 different mouse models 
were generated with targeted mutagenesis (83). The biggest problem of most of 
these models was that the mice had severe pathological complications in the 
intestines, often leading to death prior to lung disease. The transgenic Cftrtm1Unc 
Tg(FABPCFTR)1Jaw/J (Cftr-/-) mouse counteracts this problem by expressing human 
CFTR in the gut under the control of the FABP1 (fatty acid binding protein1) 
promoter, rescuing the mice from intestinal obstruction (84). These mice show 
inflammatory lung conditions, presumably due to ceramide accumulation in the 
respiratory epithelium (60), leading to an increased susceptibility to infections in aged 
mice (>16 weeks old) (85). Another study showed no correlation between age and 
susceptibility towards intratracheally applied P. aeruginosa infections, but implied that 
CF mice are a suitable model for studying early host defense mechanisms in CF (86). 
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1.4 Pseudomonas aeruginosa 
P. aeruginosa is an opportunistic, gram-negative, flagellated, rodshaped, facultative 
anaerob bacterium. It has a highly regulated big genome ranging from 5.5 – 7 Mbp 
(87) with more than 500 regulatory genes found in the PAO1 strain (88) enabling the 
survival in various environmental habitats (89, 90). P. aeruginosa is under normal 
conditions cleared by the immune system, but in immunocompromised hosts, or in 
inflammatory conditions like CF, where the host epithelium is disrupted, P. 
aeruginosa can cause severe infections. Once P. aeruginosa gets a hold in the host, 
it has several mechanisms to escape immune responses as being formation of 
biofilms (91), high intrinsic resistance to antibiotics (92) and release of virulence 
factors (93-95). It is the most predominant pathogen in CF lung disease (52).  
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2. Aim of study 
Excessive inflammation due to unbalanced T-cell responses is a major problem in 
autoinflammatory (like inflammatory bowel disease or rheumatoid arthritis) and 
infectious diseases, causing collateral damage to the host. In CF, unbalanced 
Th2/Th17 responses seem to play a major role in the persistence of the inflammatory 
state next to a high number of recruited neutrophils. Our group revealed, that CF 
patients have increased numbers of granulocytic myeloid-derived suppressor cells 
(G-MDSCs) in bronchoalveolar lavage and in peripheral blood compared to healthy 
donors, especially CF patients with chronic P. aeruginosa infections. Furthermore 
percentages of G-MDSCs positively correlated with lung function in chronic P. 
aeruginosa infected CF patients. 
The aim of this work was to further investigate how P. aeruginosa interacts with 
MDSCs in acute pulmonary infections and what impact CFTR deficiency has. Using 
in vivo infection models and Cftr-/- mice we mimicked the MDSC induction of P. 
aeruginosa infected CF patients. With further ex vivo suppression assays we 
analyzed the capability of induced MDSCs to suppress polyclonal T cell expansion. 
To assess the impact of CFTR deficiency on G-MDSC suppression of T cells, we 
compared the suppressive capability of in vitro expanded G-MDSCs from CFTR 
deficient to wildtype mice. In order to clarify if G-MDSCs are beneficial or detrimental 
in acute pulmonary P. aeruginosa infections, we adoptively transferred G-MDSCs 
into wildtype mice prior to intranasal infection and monitored the survival of the mice. 
With this study, we want to gain further insights into the role of MDSCs in P. 
aeruginosa infections in the context of CF using in vivo models in order to elaborate 
the modulation of MDSCs as a therapeutic approach in CF. 
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3. Discussion 
The aim of this study was to investigate the interaction of myeloid-derived suppressor 
cells (MDSCs) and the opportunistic pathogen P. aeruginosa in the context of cystic 
fibrosis (CF). While MDSCs have been widely studied in various cancers, where they 
are associated with tumor immune evasion and therefore negatively correlate with 
patient survival, MDSCs have also been shown to be involved in autoinflammatory 
and infectious diseases. Previous studies from our group revealed, that G-MDSCs, 
but not M-MDSCs are increased in peripheral blood of patients with CF compared to 
healthy donors. The highest increase was found in patients with chronic P. 
aeruginosa infections and correlated positively with clinical pulmonary parameters. 
Further in vitro assays, as well as in vivo pulmonary infection models in wildtype (WT) 
and Cftr-/- mice we gained more insights into the role of MDSCs in infective 
inflammatory diseases. 
3.1 P. aeruginosa infections induce MDSCs 
To investigate the role of G- and M-MDSCs upon bacterial infections, we used an 
acute pulmonary infection model in WT and Cftr-/- mice with the P. aeruginosa lab 
strain PAO1. We saw a local (lung and bronchoalveolar lavage (BAL)) and systemic 
(spleen) induction of G-MDSCs in mice after acute pulmonary P. aeruginosa 
infections. G-MDSCs seem to play the major role, as M-MDSCs were only slightly 
induced in lungs and spleens, what resembles the situation in CF patients and in vitro 
experiments with human peripheral blood mononucleated cells (PBMCs) (27). G-
MDSCs were decreased in bone marrow of infected animals and since it is a fairly 
short time of infection duration before the organs were harvested (12 – 16 h), we 
assume that G-MDSCs are mainly recruited from the bone marrow to the airways and 
spleens. Gender of the mice had no influence on basal MDSC amounts or induction 
through infection (data not shown). 
Our in vivo studies with 8 – 12 weeks old Cftrtm1Unc-Tg(FABPCFTR)1Jaw/J (Cftr-/-) 
mice revealed that CFTR deficiency has no influence on the basal amount of MDSCs 
(G- and M-MDSCs) as well as on the recruitment of MDSCs during acute pulmonary 
P. aeruginosa infections when comparing Cftr-/- to WT littermates. Further studies on 
older Cftr-/- mice might give further insights, as older Cftr-/- mice develop inflammatory 
responses due to CFTR deficiency (86), reflecting the human CF condition better. 
Another discrepancy is that CF patients often suffer from persisting bacterial 
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infections, whereas in the acute infection model in Cftr-/- mice P. aeruginosa is 
cleared efficiently within a few days (86). Therefore we will further try an artificial 
bead model with encapsulated P. aeruginosa that will mimic the bacterial persistence 
in the lungs (96). 
3.2 P. aeruginosa enhances G-MDSC activity 
Since in our recent and previous studies G-MDSCs seem to be key players in P. 
aeruginosa infections (27), our further studies were focused on G-MDSCs only. As a 
next step, we analyzed the suppressive capability of basal G-MDSCs as well as 
acute pulmonary P. aeruginosa infection induced G-MDSCs isolated from lungs, BAL 
and bone marrow of C57Bl6/J mice. In all three compartments we could demonstrate 
a dose dependent suppression of proliferation of freshly isolated splenic CD4+ T cells 
at ratios 1:1, 1:2, 1:4 and 1:8 with the highest suppression at the 1:1 G-MDSC to T-
cell ratio. G-MDSCs isolated from infected mice had an enhanced suppressive 
capability at a single cell level, indicating that P. aeruginosa infections enhance G-
MDSC activity. Intriguingly G-MDSCs had not only enhanced suppressive capabilities 
at the site of inflammation (lung), but also a systemic activation of G-MDSCs could be 
observed in G-MDSCs isolated from splenocytes and bone marrow cells. 
The cellular mechanisms that are activated in G-MDSCs following infection remain to 
be elucidated, although ROS and IL-10 production of G-MDSCs seem not to be 
involved (data not shown/ unpublished observation). Further interesting targets to 
investigate could be arginase-1 production, as it is a major suppressive mechanism 
of MDSCs (19, 32) or transforming growth factor-beta (TGF-β) secretion (41, 42). For 
the mechanism triggering G-MDSC activation via P. aeruginosa, we suspect that 
soluble mediators that are spread throughout the mice are responsible for the 
enhanced suppressive activity, as we could not detect any bacteria in spleens and 
bone marrow of infected animals. Flagellin could be the most prevalent target, as it is 
known to be shed by P. aeruginosa and has been shown to potently induce G-
MDSCs in human in vitro approaches (27), but other soluble mediators should also 
be taken into account. Another factor driving G-MDSC activation could also be 
endogenous inflammatory signals triggered the infection. 
CFTR deficient G-MDSCs on the other hand were less suppressive. While G-MDSCs 
isolated from Cftr-/- mice were still able to suppress T-cell proliferation, the 
suppressive effect on a single cell level was diminished when compared to G-MDSCs 
PhD Thesis Hasan Halit Öz                       25 
isolated from wild type littermates. As Cftr-/- mice only slowly start to develop 
inflammatory symptoms with higher age (>16 weeks) (86) and in our experiments 
cells isolated from 8 – 12 week old mice were used, this effect can most likely be 
directly linked directly to CFTR deficiency. Via this system we therefore have the 
ability to investigate cellular mechanisms linking CFTR to MDSC suppression. While 
this finding is interesting, it is yet too preliminary to draw solid conclusions for CF 
patients. If MDSCs from CF patients are also less suppressive, this could at least 
partially explain the overshooting Th2/Th17 responses of CF patients, as T-cell 
responses would be less suppressed by MDSCs. Investigation of the effect of P. 
aeruginosa infections on G-MDSCs from Cftr-/- mice could give further insights. 
3.3 G-MDSCs effect in vivo 
Recent findings from our group revealed, that adoptive transfer of G-MDSCs prior to 
systemic Candida (C) albicans (systemic candidiasis) infection improves the survival 
of infected Balb/c mice, probably by diminishing pathogen beneficial Th17 responses 
and by generally decreasing overshooting inflammatory responses (97, 98). In CF 
patients with chronic P. aeruginosa infections MDSCs positively correlated with 
clinical lung function parameters (27). Therefore we wanted to determine the 
potential protective effect of G-MDSCs by adoptively transferring G-MDSCs prior to 
pulmonary acute P. aeruginosa infection into mice. Similar to the findings in 
pulmonary Aspergillus fumigatus infections (98) adoptive transfer of G-MDSCs had 
no effect on the severity of infection as well as on the weight recovery. Higher 
concentrations of P. aeruginosa lead to death via acute sepsis (99-101) within two to 
three days, irrespective of adoptive G-MDSC transfer. Based on these findings, we 
speculate that G-MDSCs have a higher impact on systemic fungal infections (like 
systemic candidiasis) compared to acute local bacterial airway infections in vivo. 
Another explanation could be the methodological discrepancy, as both, G-MDSCs 
and C. albicans were administered intravenously, whereas P. aeruginosa was given 
intranasally. The close proximity in the systemic C. albicans infection might give the 
transferred G-MDSCs an edge, whereas in the pulmonary infections the G-MDSCs 
actively have to migrate to the site of infection from the circulation. To clarify the 
effect of local proximity, future studies have to be conducted transferring G-MDSCs 
into the airways prior to intranasal PAO1 infection. Furthermore, the beneficial effect 
of G-MDSCs on the clinical lung function parameters of chronically infected CF 
patients with chronic P. aeruginosa infections seems to be a long-term effect rather 
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than, as simulated in our model, an immediate immune response (27). Therefore it 
would be relevant to perform our in vivo studies with a chronic infection model of P. 
aeruginosa (102) combined with adoptive transfer of G-MDSCs i) systemically and ii) 
locally (intratracheal application) of bone marrow situated G-MDSCs from control 
mice, P. aeruginosa infection induced G-MDSCs and G-MDSCs from Cftr-/- mice. 
3.4 Concluding remarks 
Emerging evidence suggests that MDSCs are essential not only in malignant 
diseases, but also infectious and inflammatory diseases, for example inflammatory 
bowel disease (23), rheumatoid arthritis (24, 25), chronic obstructive pulmonary 
disease (103, 104), tuberculosis (105), sepsis (106, 107), cystic fibrosis (27). This 
study demonstrates that acute pulmonary P. aeruginosa infection recruits and 
functionally modulates G-MDSCs and thereby undermines host immunity in vivo. 
Further studies need be performed to understand the cellular mechanisms, as it 
might give insights into general MDSC recruitment and activation in infectious and 
inflammatory diseases. 
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Abstract 22 
Pseudomonas aeruginosa is an opportunistic pathogen that causes infections mainly in patients 23 
with cystic fibrosis (CF) lung disease. Despite innate and adaptive immune responses upon 24 
infection, P. aeruginosa is capable of efficiently escaping host defenses, but the underlying 25 
immune mechanisms remain poorly understood. Myeloid-derived suppressor cells (MDSCs) are 26 
innate immune cells that are functionally characterized by their potential to suppress T- and 27 
natural killer (NK)-cell responses. Here we demonstrate, using an airway in vivo infection model, 28 
that P. aeruginosa recruits and activates neutrophilic MDSCs, which functionally suppress T-cell 29 
responses. We further show that the CF gene defect (cystic fibrosis transmembrane conductance 30 
regulator, CFTR) modulates the functionality, but not the recruitment or generation of 31 
neutrophilic MDSCs. Collectively, we define a mechanism by which P. aeruginosa airway 32 
infection undermines host immunity by modulating neutrophilic MDSCs in vivo. 33 
 34 
Author Summary 35 
Infections with Pseudomonas aeruginosa, an opportunistic gram-negative bacterium, represent a 36 
major cause of morbidity and mortality in patients with cystic fibrosis (CF) lung disease. Upon 37 
airway infection, P. aeruginosa activates the innate immune system. However, in spite of a 38 
substantial and sustained presence of phagocytic and lymphocytic immune cells at the infected 39 
airway compartment, the host is not able to efficiently eliminate P. aeruginosa in CF. The 40 
underlying immune mechanisms remained poorly understood. Myeloid-derived suppressor cells 41 
(MDSCs) are anti-inflammatory innate immune cells that potently suppress T cellular immune 42 
responses. We showed in a previous study that neutrophilic MDSCs accumulate in patients with 43 
CF infected with P. aeruginosa and correlate with lung function in those patients. Here, we 44 
demonstrate that P. aeruginosa airway infection recruits and functionally activates neutrophilic 45 
MDSCs and thereby define a mechanism by which P. aeruginosa airway infection undermines 46 
host immunity by modulating neutrophilic MDSCs in vivo. 47 
 48 
Key words: myeloid-derived suppressor cells, MDSCs, bacteria, infection, Pseudomonas, CF, 49 
cystic fibrosis, CFTR, lung, T cells 50 
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Introduction 53 
Infections with Pseudomonas aeruginosa, an opportunistic gram-negative bacterium, represent a 54 
major cause of morbidity and mortality in patients with cystic fibrosis (CF) lung disease, chronic 55 
obstructive pulmonary disease (COPD), ventilated patients and patients undergoing 56 
immunosuppression (1, 2). Upon infection, P. aeruginosa activates the innate immune system 57 
and induces a rapid recruitment of neutrophilic cells to the site of inflammation, followed by 58 
activation of the adaptive response characterized by T-cell infiltration (1). Despite a substantial 59 
and sustained presence of phagocytic and lymphocytic immune cells at the infected 60 
compartment, the host is not able to efficiently eliminate P. aeruginosa, particularly in 61 
pulmonary disease conditions, such as CF (caused by mutations in the cystic fibrosis 62 
transmembrane conductance regulator, CFTR, gene) or chronic obstructive pulmonary disease 63 
(COPD, caused by cigarette smoke) (1, 3, 4). The underlying immune mechanisms remained 64 
poorly understood. 65 
Myeloid-derived suppressor cells (MDSCs) are innate immune cells that are functionally 66 
characterized by their potential to suppress T- and natural killer (NK)-cell responses (5, 6). 67 
MDSCs can be sub-divided into neutrophilic and monocytic MDSCs as defined by surface 68 
marker profiles. Rieber et al. demonstrated in a previous study that neutrophilic MDSCs 69 
accumulate in patients with CF infected with P. aeruginosa (7). We further showed that 70 
neutrophilic MDSCs are clinically relevant in P. aeruginosa-infected CF patients, because 71 
percentages of neutrophilic MDSCs correlated with lung function in those patients. However, the 72 
mechanisms by which P. aeruginosa airway infection regulates neutrophilic MDSCs in vivo 73 
remained elusive. 74 
 Here we used a well-established P. aeruginosa airway infection model (8, 9) to 75 
investigate the mechanisms by which P. aeruginosa skews host immunity in vivo. Our studies 76 
demonstrate that (i) P. aeruginosa airway infection triggers the recruitment of neutrophilic, but 77 
not monocytic MDSCs, (ii) P. aeruginosa infection enhances the suppressive capacity of 78 
neutrophilic MDSCs and (iii) CFTR partially overlaps with P. aeruginosa in modulating 79 
neutrophilic MDSCs.  80 
Oez et al. 
4 
 
Materials and Methods 81 
Ethics statement 82 
All animal studies were reviewed and approved by the Regierungspräsidium Tübingen, 83 
Tübingen, Germany (approval ID: K4/12), and were carried out according to the guidelines of 84 
the German law of protection of animal life. 85 
 86 
Bacteria 87 
P. aeruginosa wild type strains (PAO1) were used as published previously by our group (9). 88 
Strains of the culture collection were streaked on agar plates and incubated at 37°C overnight. 89 
Colonies were then inoculated into lysogeny broth overnight. The next day, a 1:10 dilution in 90 
lysogeny broth was performed and bacteria were cultured at 37°C for 4 hours. The optical 91 
density was measured at 600 nm. 92 
 93 
Mouse models 94 
Mice were bred at the animal facility of the Institute of Pharmacology (Tübingen). C57Bl/6J or 95 
Cftr
-/-
 (Cftr
tm1Unc
 -Tg(FABPCFTR)1Jaw/J) mice were used. Cftr
-/-
 mice were compared with age- 96 
and background strain-matched Cftr
+/+
 littermates. The mouse model of acute pulmonary P. 97 
aeruginosa infection was performed as published by our group (9). Mice were infected with 98 
2x10
6 
or 4x10
6 
CFU of P. aeruginosa (PAO1) utilizing previously established procedures (9). 99 
Intranasal applications were carried out under antagonizable anesthesia. Briefly, an inoculum of 100 
2x10
6 
and 4x10
6 CFU were administered intranasally (50 μl/nostril). After infection, body weight 101 
was monitored once a day over one week. For FACS analysis mice were sacrificed 16 hours after 102 
infection. 103 
 104 
MDSC in vitro generation 105 
Bone marrow cells and splenocytes were isolated from Cftr
+/+ 
and Cftr
-/-
 mice and cultured in 106 
RPMI1640 (Merck Millipore) with supplements, in detail 10 % fetal bovine serum (Sigma), 100 107 
U/ml Penicillin-Streptomycin (Merck Millipore) each, 2 mM L-Glutamine (Merck Millipore), 10 108 
mM HEPES (Merck Millipore). MDSC generation was induced by addition of 40 ng/ml 109 
recombinant mouse GM-CSF (Biolegend) and 40 ng/ml recombinant mouse IL-6 (Biolegend) as 110 
published by Marigo et al. (10). Cells were either fed with fresh media and cytokines on d3 and 111 
d6 or collected and analyzed by flow cytometry at d3, d6 and d10. For suppression assays cells 112 
were collected on d6. 113 
 114 
MDSC characterization, isolation and adoptive transfer 115 
Murine MDSCs were phenotypically characterized as described previously (11) by using CD11b, 116 
Ly6G (neutrophilic MDSCs) and Ly6C (monocytic MDSCs) markers followed by T-cell 117 
suppression assays to distinguish them from non-suppressive neutrophilic or monocytic effector 118 
cells respectively. Flow cytometry was performed on a FACS Calibur (BD). Murine MDSCs 119 
were isolated from different organs/tissues/fluids as described previously (11) using MACS 120 
(MDSC isolation kit, Miltenyi). For adoptive transfer experiments, CD11b
+
Ly6G
+
 neutrophilic 121 
MDSCs were isolated from the bone marrow of healthy female C57Bl6/J wildtype mice by 122 
MACS (MDSC isolation kit, Miltenyi Biotec, Germany). Transfer was performed by transferring 123 
8-10x10
6
 neutrophilic MDSCs per animal into eight to twelve weeks old female C57Bl6/J 124 
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wildtype mice via lateral tail vein injection. 24 hours after the neutrophilic MDSC transfer, mice 125 
were infected with P. aeruginosa (PAO1) as described above. 126 
 127 
T-cell suppression assays 128 
T-cell suppression assays were performed as described previously (11) using the CFSE method 129 
according to the manufacturer's protocol (Invitrogen). In brief, CD11b
+
Ly6G
+
 neutrophilic 130 
MDSCs were isolated from different organs/tissues/fluids by using MACS (MDSC isolation kit, 131 
Miltenyi Biotec, Germany) and were co-cultured for three days (37°C, 5% CO2) with MACS 132 
sorted CFSE stained CD4
+
 T cells from splenocytes at MDSC : T cell ratios 1:1, 1:2, 1:4 and 1:8 133 
in RPMI1640 with supplements as mentioned before. The number of T cells per well was kept at 134 
10
5 
and MDSCs were added accordingly. T-cell proliferation was stimulated with CD3/CD28-135 
beads (mouse T-cell activation kit, Miltenyi Biotec, Germany) and recombinant mouse IL-2 (50 136 
U/ml, Biolegend). CFSE-fluorescence intensity was analyzed by flow cytometry to determine the 137 
percentage of polyclonally proliferated T- cells. For the graphs the data was normalized to the 138 
proliferation of the stimulated control T-cell proliferation (without addition of MDSCs). 139 
 140 
BALF 141 
Bronchoalveolar lavage was extracted through the trachea with 2 ml PBS. Living BAL cells 142 
were counted using trypan blue dye exclusion. After erythrocyte lysis with ACK lysis solution, 143 
cells were incubated with an Fc receptor block (1 μg/1 × 106 cells; BD Bioscience) to reduce 144 
nonspecific antibody binding. 145 
 146 
Flow Cytometry       147 
The panel of antibodies used to stain BALF, lung, spleen or bone marrow cells included CD11b 148 
(clone M1/70), Ly6G (clone 1A8) and Ly6C (clone AL-21) (all from BD Biosciences). Flow 149 
cytometry was performed using BD FACS Calibur (BD Bioscience), and data were analyzed 150 
with FlowJo software. 151 
 152 
Statistics 153 
Statistical analysis was done using GraphPad Prism 6.0 (Graph Pad Software, La Jolla, CA, 154 
USA). Differences between the groups were determined by Students’ t test. A P value of <0.05 155 
was considered to be significant.  156 
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Results  157 
Pseudomonas infection triggers neutrophilic MDSC recruitment 158 
We characterized the recruitment of neutrophilic and monocytic MDSCs in response to acute P. 159 
aeruginosa airway infection in different pulmonary (BALF, lung) and extra-pulmonary (spleen, 160 
bone marrow) compartments in vivo (Figure 1A, Figure 1D, Figure 1E). To this end, we 161 
analyzed MDSCs based on their (i) phenotypic characteristics (Figure 1A) and their (ii) 162 
functional capacity to dose-dependently suppress CD4
+
 T-cell proliferation (Figure 1B, Figure 163 
1C). Utilizing these approaches we could demonstrate that acute P. aeruginosa airway infection 164 
lead to an increase of neutrophilic MDSCs in BALF and lung tissue by both percentages as well 165 
as total cell numbers and lead to an increase of MDSC percentages in the spleen (Figure 1A, 166 
Figure 1D), whereas the percentages or total cell numbers of neutrophilic MDSCs decreased in 167 
the bone marrow compartment (Figure 1D). Percentages of monocytic MDSCs remained 168 
unchanged in BALF and bone marrow but increased in lung tissue had a tendential increase in 169 
spleen, however to a far lesser extent than neutrophilic MDSCs upon P. aeruginosa airway 170 
infection (Figure 1E). Total monocytic MDSC numbers also increased in lungs upon P. 171 
aeruginosa airway infection but remained unchanged in spleen. Collectively, these studies 172 
indicate that P. aeruginosa airway infection has a substantial effect on MDSCs in vivo by 173 
triggering the recruitment of neutrophilic MDSCs into the pulmonary compartment and 174 
increasing the percentage of neutrophilic MDSCs in the spleen. 175 
 176 
Pseudomonas infection enhances the suppressive capacity of neutrophilic MDSCs 177 
Next, we sought to dissect whether acute P. aeruginosa airway infection not only recruits 178 
neutrophilic MDSCs, but also shapes their functional characteristics in terms of suppressing T-179 
cell proliferation. For this purpose, we isolated neutrophilic MDSCs from lungs, bone marrow 180 
and spleens using MACS technology and tested their capacity to suppress polyclonal T-cell 181 
proliferation (Figure 2A). These studies demonstrated that spleen-isolated neutrophilic MDSCs 182 
suppressed polyclonal T-cell proliferation in a dose-dependent manner (Figure 2B). This effect 183 
that was enhanced upon acute P. aeruginosa airway infection, but depended on its magnitude 184 
and significance on the origin of isolated neutrophilic MDSCs (bone marrow, spleens or lungs) 185 
and the MDSC-to-T-cell ratios applied (Figure 2B, Figure 2C). In general, neutrophilic MDSCs 186 
isolated from the lung had the strongest suppressive capability, followed by neutrophilic MDSCs 187 
isolated from bone marrow, while splenic neutrophilic MDSCs showed the weakest suppression 188 
of polyclonal T-cell proliferation (Figure 2C). When viewed in combination, these experiments 189 
provide evidence that (i) neutrophilic MDSCs in P. aeruginosa airway infection functionally 190 
dampen T-cell proliferation and that (ii) P. aeruginosa airway infection topically (pulmonary) 191 
and systemically enhances the suppressive capacity of neutrophilic MDSCs.  192 
 193 
Adoptive transfer of neutrophilic MDSCs has no impact on weight loss and weight recovery in 194 
acute Pseudomonas infection 195 
To assess whether neutrophilic MDSCs bear therapeutic potential in P. aeruginosa airway 196 
infection, we isolated neutrophilic MDSCs from bone marrow by MACS technology, checked 197 
their functionality ex vivo in T-cell suppression, adoptively transferred the cells i.v. prior to acute 198 
P. aeruginosa airway infection and monitored the impact of the adoptively transferred MDSCs 199 
on weight loss and weight recovery after acute P. aeruginosa airway infection (Figure 3). Two 200 
different infection doses were assessed, 2x10
6 
(Figure 3A) or 4x10
6 
(Figure 3B) CFU. These 201 
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investigations demonstrated that the adoptive transfer of neutrophilic MDSCs had no significant 202 
impact on weight loss or weight recovery upon acute P. aeruginosa airway infection at 2x10
6 
or 203 
4x10
6 
CFU (Figure 3). Both experimental groups successfully cleared the pathogen, as we could 204 
not find any residual CFU of P. aeruginosa at d5 (2x10
6
 CFU) or d6 (4x10
6
 CFU) p.i. (data not 205 
shown). 206 
 207 
CFTR modulates function, but not recruitment or generation of neutrophilic MDSCs 208 
Since P. aeruginosa airway infections play a predominant role in patients with CF, we sought to 209 
dissect the role of CFTR in regulating the recruitment and functionality of neutrophilic MDSCs 210 
in our experimental systems. For this purpose, we first analyzed whether the absence of 211 
functional CFTR has an impact on the recruitment of neutrophilic or monocytic MDSCs into the 212 
airways or into non-pulmonary compartments in vivo (Supplementary Figure 1, Supplementary 213 
Figure 2). Our data suggest that Cftr deficiency has no significant effect on the recruitment of 214 
neutrophilic MDSCs (Supplementary Figure 1) in any body compartment in vivo, when 215 
analyzing Cftr
-/-
 mice compared to Cftr
+/+
 mice. Cftr deficiency also had no significant effect on 216 
the recruitment of monocytic MDSCs (Supplementary Figure 2), although the total numbers of 217 
monocytic MDSCs were decreased in the bone marrow of Cftr
-/-
 mice compared to Cftr
+/+
. Next, 218 
we assessed whether the lack of CFTR has an effect on the in vitro generation of neutrophilic 219 
MDSCs (Supplementary Figure 3). Consistent with the in vivo recruitment studies, these 220 
analyses showed that the lack of CFTR had no effect on the generation of neutrophilic MDSCs in 221 
vitro (Supplementary Figure 3). Finally, we sought to determine whether the absence of CFTR 222 
has a functional consequence for neutrophilic MDSCs in MDSC - T cell interaction assays. In 223 
contrast to the recruitment and generation studies, these functional assays provided evidence that 224 
in vitro generated Cftr
-/-
 neutrophilic MDSCs were impaired in suppressing T-cell proliferation 225 
compared to their Cftr
+/+
 counterpart cells, most strongly at a 1:4 and 1:8 MDSC : T-cell ratios 226 
(Figure 4). In summary, these investigations demonstrated that CFTR has no effect on the 227 
recruitment or generation of MDSCs, but regulates, at least partially, MDSC-mediated T-cell 228 
suppression.  229 
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Discussion 230 
MDSC generation and functionalities have been studied thoroughly in several types of cancer 231 
(12-18), yet their regulation and functional role in infectious disease conditions remained poorly 232 
defined. Here we studied the role of MDSCs in the setting of airway P. aeruginosa infection, 233 
which is highly relevant for several human diseases, particularly CF, COPD, ventilation-234 
associated pneumonia and burn-related infections (2, 19-21).  235 
These present studies build on previous findings from our group demonstrate that (i)  236 
P. aeruginosa airway infections in patients with CF were associated with increased percentages 237 
of neutrophilic MDSCs in the peripheral blood and that (ii) percentages of circulating 238 
neutrophilic MDSCs in P. aeruginosa infected CF patients were positively correlated with the 239 
lung function outcome (7). Despite these intriguing results, we so far do not have any 240 
mechanistic explanation(s) how P. aeruginosa infection modulates MDSC recruitment and 241 
function and why, unexpectedly, percentages of circulating neutrophilic MDSCs were associated 242 
with a beneficial disease outcome in patients with CF lung disease. To dissect this host-pathogen 243 
interaction in vivo, we systematically investigated the MDSCs in different immune and airway 244 
compartments in a well-established model of acute P. aeruginosa infection (8). Our results here 245 
confirmed and extended previous findings obtained from human CF patients that P. aeruginosa 246 
infections induced MDSC subsets, mainly being neutrophilic MDSCs. In vivo, acute P. 247 
aeruginosa airway infections triggered neutrophilic MDSC recruitment from the bone marrow 248 
into bronchoalveolar and pulmonary compartments, where neutrophilic MDSCs were 249 
functionally active in suppressing polyclonal effector T-cell responses. 250 
Intriguingly, acute bacterial P. aeruginosa airway infections not only recruited 251 
neutrophilic MDSCs to the infected airway compartment, but also enhanced, at least partially, 252 
their T-cell suppressive potential at a single cell level, surprisingly even at sites distant from the 253 
primary site of airway infection, such as the bone marrow. The underlying mechanisms for this 254 
phenomenon remain to be solved in the future, but based on our previous finding that 255 
neutrophilic MDSCs express Toll-like receptor 5 (TLR5) (7) and its ligand flagellin is shed from 256 
P. aeruginosa bacteria and can be found in the circulation after P. aeruginosa airway infections 257 
(Hartl et. al., unpublished observation), we tempt to speculate that P. aeruginosa-derived 258 
pathogen-associated molecular patterns (PAMPs), prototypically flagellin, skew neutrophilic 259 
MDSCs systemically, including the bone marrow compartment, to boost their 260 
immunosuppressive functionalities, a hypothesis remaining to be tested in future investigations. 261 
Overall, the precise in vivo kinetics, dynamics and compartmentalizations in the complex setting 262 
of P. aeruginosa infection remain to be deciphered in future in vivo studies. 263 
Besides P. aeruginosa infection, we assessed the effect of Cftr deficiency on the 264 
induction and function of neutrophilic MDSCs, as it is pathophysiological the case for CF 265 
patients in vivo (7). Our in vivo model, however, failed to identify a significant role for Cftr in 266 
MDSCs homeostasis, at least in our experimental settings, since Cftr deficient mice displayed the 267 
same amounts of neutrophilic MDSCs as their wildtype littermates in BALF, lungs, spleens and 268 
bone marrow, precluding a major effect of Cftr. We also observed no difference on the 269 
recruitment and accumulation of neutrophilic MDSCs in BALF and lungs of Cftr deficient mice 270 
compared to wildtype littermates upon acute pulmonary P. aeruginosa infection in vivo as well 271 
as on neutrophilic MDSC generation in vitro.  272 
In contrast to the neutrophilic MDSC-enhancing effect of P. aeruginosa infections, Cftr 273 
deficiency, however, differentially modulated the suppressive capability of in vitro-expanded 274 
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neutrophilic MDSCs. The underlying mechanism requires further investigation, particularly 275 
given the complex role of Cftr deficiency in driving a hyper-inflammatory micromilieu (22, 23) 276 
associated with MDSC induction (7, 24). A possible explanation for the diminished suppressive 277 
activity of Cftr
-/-
 neutrophilic MDSCs could be a scenario where MDSCs may lose their 278 
suppressive function via inflammasome activity, as discussed by Koehn et al. (25). 279 
Monocytic MDSC recruitment was also not affected by Cftr deficiency, yet the total 280 
amount of cells in bone marrow of Cftr
-/-
 mice was diminished compared to Cftr
+/+
 littermates, 281 
leading to a decreased net total amount of monocytic MDSCs in bone marrow. In-depth 282 
characterization of this phenomenon was, however, beyond the scope of this study, as the focus 283 
lied mainly on neutrophilic MDSCs, the major CF-relevant MDSC population (7). 284 
 Inspired by previous findings from our group that adoptive transfer of neutrophilic 285 
MDSCs was protective in an invasive/systemic in vivo fungal infection model (11), we tested the 286 
potential of adoptively transferred neutrophilic MDSCs to affect the outcome of P. aeruginosa 287 
infection in vivo. However, in our bacterial infection model, the adoptive transfer of neutrophilic 288 
MDSCs did not affect the weight loss and/or weight recovery of P. aeruginosa infected mice and 289 
the bacterial clearance at d5 or d6 p.i.. Based on these findings, we speculate that neutrophilic 290 
MDSCs have a more substantial impact on invasive/systemic fungal infections compared to 291 
compartmentalized P. aeruginosa airway infections in vivo. The precise mechanisms underlying 292 
this difference remain to be defined, but may relate to the fact that in invasive/systemic fungal 293 
infections the protective effect of MDSCs was conferred by MDSCs adoptively transferred i.v., 294 
the same route as fungal pathogens were inoculated, whereas in contrast in the case of P. 295 
aeruginosa airway infections, bacteria were inoculated topically into the airways (intranasally) 296 
while MDSCs were adoptively transferred i.v.. Consequently, in systemic fungal infections both 297 
fungal pathogens and MDSCs were in close proximities, whereas in the case of P. aeruginosa 298 
airway infections, MDSCs would have to actively enter the airway compartment from the 299 
circulation. 300 
Our study has several limitations. (i) We were using an acute P. aeruginosa infection model for 301 
our proof-of-concept MDSC studies; yet a chronic infection/ colonization model, which is much 302 
harder to standardize and read-out, would resemble the situation of CF patients more closely; a 303 
tast for future investigations; (ii) our studies were unable to identify the molecular mechanisms 304 
by which P. aeruginosa/P. aeruginosa-derived factors enhance neutrophilic MDSC activity. 305 
Preliminary studies failed to demonstrate significant involvements of ROS and IL-10 (data not 306 
shown), issues requiring further immunological and biochemical studies; (iii) lymphocytes 307 
express Cftr, suggesting that Cftr in T cells could affect the functional outcome of MDSC-Tcell 308 
interactions in CF lung disease, though preliminary data from our group showed no significant 309 
impact of T cellular Cftr on MDSC-T cell studies (data not shown); (iv) we observed in our 310 
suppression assays that beyond CD4
+
 cells, also non-CD4
+
 cells in the fraction of lymphocytes 311 
were proliferating. While we have no clear explanation for this observation and its 312 
immunological relevance, we speculate that these non-CD4
+ 
T cells may arise due to the high 313 
stimulation trigger during our culture conditions. As the population consistently appeared 314 
throughout the experiments, we expect no substantial influence on the outcome of our respective 315 
read-out studies; (v) data and knowledge on the dynamics and kinetics of adoptively transferred 316 
MDSCs in vivo are limited. Preliminary investigations showed that neutrophilic MDSCs reach 317 
lungs of mice within 24 h after lateral tail vein injection (data not shown). It is further known 318 
from previous studies that adoptively transferred MDSCs can be recovered from splenocytes 5 319 
days post injection (25), yet studies focusing on the kinetics and dynamics of adoptively 320 
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transferred MDSCs in the pulmonary compartment are lacking to the best of our current 321 
knowledge; (vi) Our adoptive transfer study lacks further in-depth readouts, such as lung 322 
inflammation parameters, amounts and characteristics of parenchymal T cells or kinetics on 323 
pathogen clearance. Since our MDSC adoptive transfer studies did not reveal any impact of 324 
MDSCs on morbidity, we did restrict our read-outs to the minimum. Further studies are required 325 
to dissect the temporal and spatial in vivo kinetics and dynamics of MDSCs and T cells in the 326 
infected pulmonary compartment. 327 
 328 
Collectively, when viewed in combination, this study demonstrates that acute P. aeruginosa 329 
airway infection recruits and functionally modulates neutrophilic myeloid-derived suppressor 330 
cells and thereby defines a mechanism by which P. aeruginosa undermines host immunity in 331 
vivo by modulating neutrophilic MDSCs.  332 
Oez et al. 
11 
 
Acknowledgements  333 
We thank the lab team for its support. 334 
  335 
Oez et al. 
12 
 
References 336 
1. Hartl, D., A. Gaggar, E. Bruscia, A. Hector, V. Marcos, A. Jung, C. Greene, G. 337 
McElvaney, M. Mall, and G. Doring. 2012. Innate immunity in cystic fibrosis lung 338 
disease. J Cyst Fibros 11: 363-382. 339 
2. Williams, B. J., J. Dehnbostel, and T. S. Blackwell. 2010. Pseudomonas aeruginosa: host 340 
defence in lung diseases. Respirology 15: 1037-1056. 341 
3. Mall, M. A., and D. Hartl. 2014. CFTR: cystic fibrosis and beyond. Eur Respir J 44: 342 
1042-1054. 343 
4. Yonker, L. M., C. Cigana, B. P. Hurley, and A. Bragonzi. 2015. Host-pathogen interplay 344 
in the respiratory environment of cystic fibrosis. J Cyst Fibros. 345 
5. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators 346 
of the immune system. Nat Rev Immunol 9: 162-174. 347 
6. Gantt, S., A. Gervassi, H. Jaspan, and H. Horton. 2014. The role of myeloid-derived 348 
suppressor cells in immune ontogeny. Frontiers in immunology 5: 387. 349 
7. Rieber, N., A. Brand, A. Hector, U. Graepler-Mainka, M. Ost, I. Schafer, I. Wecker, D. 350 
Neri, A. Wirth, L. Mays, S. Zundel, J. Fuchs, R. Handgretinger, M. Stern, M. Hogardt, G. 351 
Doring, J. Riethmuller, M. Kormann, and D. Hartl. 2013. Flagellin Induces Myeloid-352 
Derived Suppressor Cells: Implications for Pseudomonas aeruginosa Infection in Cystic 353 
Fibrosis Lung Disease. J Immunol 190: 1276-1284. 354 
8. Munder, A., and B. Tummler. 2014. Assessing Pseudomonas virulence using mammalian 355 
models: acute infection model. Methods Mol Biol 1149: 773-791. 356 
9. Hector, A., H. Schafer, S. Poschel, A. Fischer, B. Fritzsching, A. Ralhan, M. Carevic, H. 357 
Oz, S. Zundel, M. Hogardt, M. Bakele, N. Rieber, J. Riethmueller, U. Graepler-Mainka, 358 
M. Stahl, A. Bender, J. S. Frick, M. Mall, and D. Hartl. 2015. Regulatory T Cell 359 
Impairment in Cystic Fibrosis Patients with Chronic Pseudomonas Infection. Am J Respir 360 
Crit Care Med. 361 
10. Marigo, I., E. Bosio, S. Solito, C. Mesa, A. Fernandez, L. Dolcetti, S. Ugel, N. Sonda, S. 362 
Bicciato, E. Falisi, F. Calabrese, G. Basso, P. Zanovello, E. Cozzi, S. Mandruzzato, and 363 
V. Bronte. 2010. Tumor-induced tolerance and immune suppression depend on the 364 
C/EBPbeta transcription factor. Immunity 32: 790-802. 365 
11. Rieber, N., A. Singh, H. Oz, M. Carevic, M. Bouzani, J. Amich, M. Ost, Z. Ye, M. 366 
Ballbach, I. Schafer, M. Mezger, S. N. Klimosch, A. N. Weber, R. Handgretinger, S. 367 
Krappmann, J. Liese, M. Engeholm, R. Schule, H. R. Salih, L. Marodi, C. Speckmann, B. 368 
Grimbacher, J. Ruland, G. D. Brown, A. Beilhack, J. Loeffler, and D. Hartl. 2015. 369 
Pathogenic fungi regulate immunity by inducing neutrophilic myeloid-derived suppressor 370 
cells. Cell Host Microbe 17: 507-514. 371 
12. Marvel, D., and D. I. Gabrilovich. 2015. Myeloid-derived suppressor cells in the tumor 372 
microenvironment: expect the unexpected. J Clin Invest 125: 3356-3364. 373 
13. Draghiciu, O., J. Lubbers, H. W. Nijman, and T. Daemen. 2015. Myeloid derived 374 
suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. 375 
Oncoimmunology 4: e954829. 376 
14. Diaz-Montero, C. M., J. Finke, and A. J. Montero. 2014. Myeloid-derived suppressor 377 
cells in cancer: therapeutic, predictive, and prognostic implications. Seminars in oncology 378 
41: 174-184. 379 
Oez et al. 
13 
 
15. Youn, J. I., V. Kumar, M. Collazo, Y. Nefedova, T. Condamine, P. Cheng, A. Villagra, S. 380 
Antonia, J. C. McCaffrey, M. Fishman, A. Sarnaik, P. Horna, E. Sotomayor, and D. I. 381 
Gabrilovich. 2013. Epigenetic silencing of retinoblastoma gene regulates pathologic 382 
differentiation of myeloid cells in cancer. Nat Immunol 14: 211-220. 383 
16. Wesolowski, R., J. Markowitz, and W. E. Carson, 3rd. 2013. Myeloid derived suppressor 384 
cells - a new therapeutic target in the treatment of cancer. Journal for immunotherapy of 385 
cancer 1: 10. 386 
17. Bruchard, M., G. Mignot, V. Derangere, F. Chalmin, A. Chevriaux, F. Vegran, W. 387 
Boireau, B. Simon, B. Ryffel, J. L. Connat, J. Kanellopoulos, F. Martin, C. Rebe, L. 388 
Apetoh, and F. Ghiringhelli. 2013. Chemotherapy-triggered cathepsin B release in 389 
myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor 390 
growth. Nat Med 19: 57-64. 391 
18. Filipazzi, P., V. Huber, and L. Rivoltini. 2012. Phenotype, function and clinical 392 
implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol 393 
Immunother 61: 255-263. 394 
19. Hogardt, M., and J. Heesemann. 2010. Adaptation of Pseudomonas aeruginosa during 395 
persistence in the cystic fibrosis lung. International journal of medical microbiology : 396 
IJMM 300: 557-562. 397 
20. Jensen, P. O., M. Givskov, T. Bjarnsholt, and C. Moser. 2010. The immune system vs. 398 
Pseudomonas aeruginosa biofilms. Fems Immunol Med Mic 59: 292-305. 399 
21. Pillarisetti, N., E. Williamson, B. Linnane, B. Skoric, C. F. Robertson, P. Robinson, J. 400 
Massie, G. L. Hall, P. Sly, S. Stick, S. Ranganathan, and A. Cf. 2011. Infection, 401 
Inflammation, and Lung Function Decline in Infants with Cystic Fibrosis. Am J Respir 402 
Crit Care Med 184: 75-81. 403 
22. Corvol, H., C. Fitting, K. Chadelat, J. Jacquot, O. Tabary, M. Boule, J. M. Cavaillon, and 404 
A. Clement. 2003. Distinct cytokine production by lung and blood neutrophils from 405 
children with cystic fibrosis. American journal of physiology. Lung cellular and 406 
molecular physiology 284: L997-1003. 407 
23. Livraghi-Butrico, A., E. J. Kelly, E. R. Klem, H. Dang, M. C. Wolfgang, R. C. Boucher, 408 
S. H. Randell, and W. K. O'Neal. 2012. Mucus clearance, MyD88-dependent and 409 
MyD88-independent immunity modulate lung susceptibility to spontaneous bacterial 410 
infection and inflammation. Mucosal Immunol 5: 397-408. 411 
24. Ballbach, M., T. Hall, A. Brand, D. Neri, A. Singh, I. Schaefer, E. Herrmann, S. 412 
Hansmann, R. Handgretinger, J. Kuemmerle-Deschner, D. Hartl, and N. Rieber. 2016. 413 
Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic 414 
Syndromes. J Innate Immun 8: 493-506. 415 
25. Koehn, B. H., P. Apostolova, J. M. Haverkamp, J. S. Miller, V. McCullar, J. Tolar, D. H. 416 
Munn, W. J. Murphy, W. J. Brickey, J. S. Serody, D. I. Gabrilovich, V. Bronte, P. J. 417 
Murray, J. P. Ting, R. Zeiser, and B. R. Blazar. 2015. GVHD-associated, inflammasome-418 
mediated loss of function in adoptively transferred myeloid-derived suppressor cells. 419 
Blood 126: 1621-1628. 420 
 421 
  422 
Oez et al. 
14 
 
Author contributions 423 
H.Ö., B.Z., C.S. and P.V. performed in vitro and in vivo experiments. C.S. contributed to 424 
reagents and analysis tools. M.C. and N.F. performed in vivo experiments. D.H., A.H., H.Ö., and 425 
N.R. designed the study, supervised experiments and wrote the manuscript. H.Ö. and D.H. 426 
analyzed the data. 427 
 428 
Financial Disclosure   429 
This work was supported by the German Research Foundation (RI 2511/2-1 to N.R., Deutsche 430 
Forschungsgemeinschaft, Emmy Noether Programme HA 5274/3-1 to D.H., the CRC/SFB685 to 431 
D.H.). The funders had no role in study design, data collection and analysis, decision to publish, 432 
or preparation of the manuscript.  433 
 
Competing Interests  
 
The authors have declared that no competing interests exist. 434 
 435 
  436 
Oez et al. 
15 
 
Fig 1 Pseudomonas aeruginosa airway infection recruits MDSCs 437 
(A) Neutrophilic (PMN-) MDSCs and monocytic (M-) MDSCs in BALF, lung, bone marrow and 438 
spleen were sequentially gated based on FSC/SSC, CD11b, Ly6G and Ly6C. PMN-MDSCs were 439 
assessed as CD11b
+
Ly6G
+
Ly6C
intermediate
, M-MDSCs as CD11b
+
Ly6C
+
Ly6G
low
. 440 
(B) Left panel: Gating strategy to assess CD4
+
 T cell proliferation using CFSE staining and flow 441 
cytometry. CD4
+ 
cells were gated from the lymphocyte population in FSC/SSC and further gated 442 
for CD4
+
. T-cell proliferation was assessed based on the CFSE fluorescence of CD4
+
 T cells. 443 
Right panel: Representative histograms of co-cultured PMN-MDSCs isolated from BALF of 444 
PAO-1 infected mice and T cells at ratios 1:1, 1:2, 1:4 and 1:8 as indicated. 445 
(C)  Ratio-dependent (suppressed) proliferation of CD4
+
 T cells by co-culturing with 446 
neutrophilic MDSCs isolated from BALF of P. aeruginosa-infected mice is shown. The values 447 
are normalized to the proliferation of activated T cells without addition of MDSCs (T cells only) 448 
as indicated as proliferation index. 449 
(D) Percentages (top row) and total amounts (bottom row) of neutrophilic MDSCs in BALF, 450 
lung, bone marrow and spleen in acute P. aeruginosa infection compared to non-infected control 451 
animals. Percentages of neutrophilic MDSCs (PMN-MDSCs) were acquired as % of 452 
CD11b
+
Ly6G
+
Ly6C
intermediate
 cells of viable cells (see Fig 1A). Total cell amounts were 453 
calculated from cell counts of single cell suspensions from isolated organs/tissues/fluids prior to 454 
FACS staining.   ** p<0.01 455 
(E) Percentages (top row) and total amounts (bottom row) of monocytic MDSCs in BALF, lung, 456 
bone marrow and spleen in acute P. aeruginosa infection compared to non-infected control 457 
animals. Percentages of monocytic MDSCs (M-MDSCs) were acquired as % of 458 
CD11b
+
Ly6C
+
Ly6G
low
 cells of viable cells (see Fig 1A). Total cell amounts were calculated 459 
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from cell counts of single cell suspensions from isolated organs/tissues/fluids prior to FACS 460 
staining. ** p<0.01 461 
Fig 2 Pseudomonas aeruginosa airway infection functionally modulates MDSCs 462 
After P. aeruginosa airway infection CD11b
+
Ly6G
+
 neutrophilic MDSCs were isolated from the 463 
lung, the bone marrow or the spleens and tested for their potential to suppress polyclonal T cell 464 
proliferation. T-cell suppression assays were performed as described previously (11) using the 465 
CFSE method. In brief, isolated CD11b
+
Ly6G
+
 neutrophilic MDSCs were co-cultured for three 466 
days (37°C, 5% CO2) with T cells (CD4
+
 splenocytes) at MDSC : T cell ratios 1:1, 1:2, 1:4 and 467 
1:8. T cells were activated with CD3/CD28-beads and recombinant mouse IL-2. CFSE-468 
fluorescence intensity was analyzed by flow cytometry to determine polyclonal T-cell 469 
proliferation. 470 
(A) Strategy to assess the effect of acute P. aeruginosa infection on MDSC-mediated T-cell 471 
suppression ex vivo. CD4
+
 T cells were isolated by MACS from splenocytes of C57Bl6/J mice 472 
and stained with CFSE. Ly6G
+
 cells were isolated from lungs, bone marrow and spleens of 473 
infected and control C57Bl6/J mice. The isolated cells were co-cultured under T-cell 474 
proliferative conditions (with CD3-CD28-coupled beads and rIL-2), collected after 3 days 475 
incubation at 37°C 5% CO2, stained for CD4 and analyzed by flow cytometry. 476 
(B) Representative histograms showing CFSE stained control CD4
+
 T-cell proliferation (top) and 477 
the suppressed proliferation caused by co-culture with isolated neutrophilic MDSCs (see Fig 2A) 478 
from spleens of PBS treated (left) and P. aeruginosa infected (right) C57Bl6/J mice with 479 
decreasing PMN-MDSC : T-cell ratios (1:1, 1:2, 1:4 and 1:8). Each peak represents one cycle of 480 
cell division. 481 
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(C) Graph showing the proliferation of T cells under T-cell proliferative conditions when co-482 
cultured with suppressive neutrophilic MDSCs isolated from bone marrow, spleens and lungs of 483 
PBS treated or PAO1 infected C57BL6/J mice (see Fig 2A). T-cell proliferation was assessed 484 
based on CFSE fluorescence of CD4
+
 T cells. (see Fig1B). Shown are MDSC : T-cell ratios of 485 
1:1 and 1:2. The values are normalized to the proliferation of activated T cells without addition 486 
of MDSCs (T cells only), indicated as proliferation index. * p<0.05 487 
Fig 3 Adoptive transfer of neutrophilic MDSCs has no impact on weight loss and weight 488 
recovery in acute Pseudomonas infection 489 
For adoptive transfer experiments, CD11b
+
Ly6G
+
 neutrophilic MDSCs were isolated from the 490 
bone marrow of wildtype mice by MACS. Transfer was performed by transferring 8-10x10
6
 491 
neutrophilic MDSCs per animal into wildtype mice via lateral tail vein injection. 24 hours after 492 
the neutrophilic MDSC transfer, mice were infected with doses of 2x10
6 
(A) or 4x10
6 
(B) CFU P. 493 
aeruginosa (PAO1) as described above in detail and weight loss was monitored. 494 
Fig 4 Role of CFTR in MDSC functionality 495 
Neutrophilic MDSCs were isolated from 6 days in vitro expanded splenocytes in supplemented 496 
RPMI and GM-CSF and IL-6 of Cftr
+/+
 and Cftr
-/-
 mice and tested for their potential to suppress 497 
polyclonal T cell proliferation. T-cell suppression assays were performed as described previously 498 
(11) using the CFSE method. In brief, bone marrow isolated Cftr
+/+
 or Cftr
-/-
 CD11b
+
Ly6G
+
 499 
neutrophilic MDSCs were co-cultured for three days (37°C, 5% CO2) with T cells (CD4
+
 500 
splenocytes) at MDSC : T cell ratios 1:1, 1:2, 1:4 and 1:8. T cells were activated with 501 
CD3/CD28-beads and recombinant mouse IL-2. CFSE-fluorescence of CD4
+
 T cells was 502 
analyzed by flow cytometry to determine polyclonal T- cell proliferation. The values are 503 
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normalized to the proliferation of activated T cells without addition of MDSCs (T cells only), 504 
indicated as proliferation index. ** p<0.01 505 
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Fig S1 Role of CFTR in PMN-MDSC recruitment 
Percentages (A) and total cell amounts (B) of PMN-MDSCs in BALF, lung, bone marrow and spleen 16h after acute P. aeruginosa 
infection in Cftr+/+ and Cftr-/- mice compared to PBS treated mice. Percentages were acquired as % of Ly6G+CD11b+Ly6Cintermediate cells 
of viable cells (see Fig 1A). Total cell amounts were calculated from cell counts of single cell suspensions from isolated 
organs/tissues/fluids prior to FACS staining.  Filled circles represent Cftr+/+ while clear circles represent Cftr-/- mice. Each circle 
represents a biological replicate, n numbers are indicated under each bar. For details see methods. * p<0.05; ** p<0.01; *** p<0.001 
A. B. 
n=3      n=13   n=3    n=14 n=3    n=13   n=3    n=14 n=8    n=12   n=8    n=12 n=8     n=12   n=8    n=12 
n=10   n=16   n=11   n=16 n=8    n=14   n=10   n=14 
n=10   n=16  n=11   n=16 n=8    n=14   n=10   n=14 
Supp Figure 2 
- + - +
0
5
1 0
1 5
2 0
 B A L F
M
-M
D
S
C
s
 [
%
]
P . a e ru g in o s a
C ft r
+ / +
C ft r
- / -
- + - +
0
5
1 0
1 5
2 0
L u n g
M
-M
D
S
C
s
 [
%
]
P . a e ru g in o s a
* *
* *
- + - +
0
5
1 0
1 5
2 0
B o n e  m a r r o w
M
-M
D
S
C
s
 [
%
]
P . a e ru g in o s a - + - +
0
1
2
3
4
5
S p le e n
M
-M
D
S
C
s
 [
%
]
P . a e ru g in o s a
*
A. B. 
Fig S1 Role of CFTR in M-MDSC recruitment 
Percentages (A) and total cell amounts (B) of M-MDSCs in BALF, lung, bone marrow and spleen 16h after acute P. aeruginosa infection 
in Cftr+/+ and Cftr-/- mice compared to PBS treated mice. Percentages were acquired as % of Ly6C+CD11b+Ly6Glow cells of viable cells 
(see Fig 1A). Total cell amounts were calculated from cell counts of single cell suspensions from isolated organs/tissues/fluids prior to 
FACS staining. Filled circles represent Cftr+/+ while clear circles represent Cftr-/- mice. Each circle represents a biological replicate, n 
numbers are indicated under each bar. For details see methods. * p<0.05; ** p<0.01 
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Fig S3 Role of CFTR in MDSC generation 
(A) MDSC generation approach. Bone marrow cells and splenocytes were isolated from Cftr+/+ and Cftr-/- mice and cultured in RPMI1640 
(Merck Millipore) with supplements (for details see methods section). MDSC generation was induced by addition of 40 ng/ml rmGM-CSF 
and 40 ng/ml rmIL-6. Cells were either fed with fresh media and cytokines on d3 and d6 or collected and analyzed by flow cytometry at d3, 
d6 and d10. 
(B) Percentages of Ly6G+CD11b+Ly6Cim cells at d0 (n=6), d3 (n=1), d6 (n=6) and d10 (n=3) generated from in vitro expanded Cftr+/+ and 
Cftr-/- bone marrow cells (top) and splenocytes (bottom). 
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SUMMARY
Despite continuous contact with fungi, immuno-
competent individuals rarely develop pro-inflamma-
tory antifungal immune responses. The underlying
tolerogenic mechanisms are incompletely under-
stood. Using both mouse models and human
patients, we show that infection with the human
pathogenic fungi Aspergillus fumigatus and Candida
albicans induces a distinct subset of neutrophilic
myeloid-derived suppressor cells (MDSCs), which
functionally suppress T and NK cell responses.
Mechanistically, pathogenic fungi induce neutro-
philic MDSCs through the pattern recognition
receptor Dectin-1 and its downstream adaptor
protein CARD9. Fungal MDSC induction is further
dependent on pathways downstream of Dectin-1
signaling, notably reactive oxygen species (ROS)
generation as well as caspase-8 activity and
interleukin-1 (IL-1) production. Additionally, exoge-
nous IL-1b induces MDSCs to comparable levels
observed during C. albicans infection. Adoptive
transfer and survival experiments show that MDSCs
are protective during invasive C. albicans infection,
but not A. fumigatus infection. These studies define
an innate immune mechanism by which pathogenic
fungi regulate host defense.
INTRODUCTION
At mucosal sites, the human immune system is faced continu-
ously with microbes, rendering fine-tuned immune responses
essential to protect against pathogenic, while maintaining
tolerance against harmless, species. This immune balance is
of particular relevance for fungi, inhaled daily as spores or pre-
sent in the gut microflora as commensal yeasts (Romani, 2011).
While immunocompetent individuals do not develop invasive
fungal infections, infections are a major problem in patients
undergoing immunosuppression, for instance, at solid organ
or hematopoietic stem cell transplantation (Garcia-Vidal et al.,
2013).
Fungi are recognized through pattern recognition receptors,
mainly C-type lectin receptors (with Dectin-1 as the prototypic
one) (Steele et al., 2005), toll-like receptors (TLRs), and pen-
traxin 3 (PTX3) (Garlanda et al., 2002; Werner et al., 2009). A
certain level of inflammation is essential to control fungal infec-
tions (Brown, 2010), but hyperinflammatory responses seem to
cause more harm than good to the host. Particularly, Th17-
driven hyperinflammatory responses have been shown to
promote fungal growth (Zelante et al., 2012), to impair fungal
clearance, and to drive tissue damage (Romani et al., 2008;
Zelante et al., 2007). Generation of reactive oxygen species
(ROS), indoleamine 2,3-dioxygenase (IDO) activity, and activa-
tion of the TIR domain-containing adaptor-inducing interferon-b
(TRIF) pathway were found to limit hyperinflammatory re-
sponses toward Aspergillus fumigatus (Romani, 2011; Romani
et al., 2009). Yet, the cellular mechanisms by which fungi
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control T cell activation and maintain tolerogenic host-path-
ogen bistability remain incompletely understood.
Myeloid-derived suppressor cells (MDSCs) are innate immune
cells characterized by their capacity to suppress T cell re-
sponses (Gabrilovich and Nagaraj, 2009). MDSCs comprise a
neutrophilic and amonocytic subset. While the functional impact
of MDSCs in cancer is established, their role in host-pathogen
interactions is poorly defined. We hypothesized that fungal
infections induce MDSCs that modulate disease outcome.
RESULTS
We analyzed the effect of the human-pathogenic fungi
A. fumigatus andC. albicans on human immune cells and noticed
the appearance of a cell population that was different from
monocytes (CD14), and expressed the myeloid markers
CD33+, CD11b+, CD16+, and CXCR4 (Figures 1A and S1A).
Fungi-induced myeloid cells strongly suppressed both CD4+
and CD8+ T cell proliferation in a dose-dependent manner
(Figure 1B), which defines MDSCs. Fungi-induced MDSCs also
suppressed innate natural killer (NK) cell responses, without
affecting cell survival (Figure S2). In contrast to growth factor-
induced MDSCs, fungi-induced MDSCs dampened Th2
responses, which play essential roles in fungal asthma (Kreindler
et al., 2010) (Figure S1B). We quantified MDSCs in patients
with invasive fungal infections and challenged mice with
A. fumigatus or C. albicans. MDSCs accumulated in both
A. fumigatus- and C. albicans-infected patients compared to
healthy and disease control patients without fungal infections
(Figure 1C). Murine studies further showed that systemic or pul-
monary fungal challenge with C. albicans (invasive disseminated
candidiasis) or A. fumigatus (pulmonary aspergillosis), as the
clinically relevant routes of infection, dose-dependently trig-
gered the recruitment of MDSCs in both immunocompetent
and immunosuppressed conditions, with a stronger MDSC
induction seen in immunocompetent animals (Figures 1D and
S1C). MDSCs expressed neutrophilic markers in both man and
mice, resembling the neutrophilic subtype of MDSCs (Rieber
et al., 2013), while monocytic MDSC subsets were not induced
(Figure S1D). Fungi-induced MDSCs functionally suppressed
T cell proliferation (Figure 1C), while autologous conventional
neutrophils failed to do (Figure S1E).
We adoptively transferred T cell-suppressive neutrophilic
MDSCs and monitored their impact on survival in fungal infec-
tion. While a single dose of adoptively transferred MDSCs was
protective in systemic C. albicans infection, MDSCs had no
impact on A. fumigatus infection (Figure 1E). Septic shock deter-
mines mortality in candidiasis (Spellberg et al., 2005), and the
interplay of fungal growth and renal immunopathology was
shown to correlate with host survival (Lionakis et al., 2011,
2013; Lionakis and Netea, 2013; Spellberg et al., 2003). Adop-
tively transferred MDSCs dampened renal T and NK cell activa-
tion and systemic Th17 and TNF-a cytokine responses (Figures
S1F and S1G). Conversely, supplementing IL-17A dampened
the MDSC-mediated protective effect (Figure 2A). Besides these
immunomodulatory effects, MDSCs might also act directly anti-
fungal, as our in vitro studies showed that they can phagocytose
and kill fungi (Figure 2B). However, direct antifungal effects could
hardly explain the beneficial effect of MDSCs in candidiasis: (i)
adoptively transferred MDSCs had no effect on fungal burden
in vivo (Figure 2A), (ii) inhibition of phagocytosis only partially
diminished the protection conferred by MDSCs (Figure 2A),
and (iii) MDSCs were exclusively protective in immunocompe-
tent mice (C. albicans infection model), with no effect in immuno-
suppressed (neutropenic) mice (A. fumigatus infection model).
The potency of A. fumigatus to induce MDSCs was most
pronounced for germ tubes and hyphae, morphotypes charac-
teristic for invasive fungal infections (Figure 1A) (Aimanianda
et al., 2009; Hohl et al., 2005; Moyes et al., 2010). The MDSC-
inducing fungal factor was present in conditioned supernatants
and was heat resistant (Figure 3A), pointing to b-glucans as the
bioactive component. We therefore focused on Dectin-1 as
b-glucan receptor and key fungal sensing system in myeloid
cells. Fungi-induced MDSCs expressed Dectin-1, and blocking
Dectin-1 prior to fungal exposure diminished the MDSC-
inducing effect, while blocking of TLR 4 had no effect (Figures
3B and S3). Furthermore, Dectin-1 receptor activation mimicked
the generation of neutrophilic MDSCs phenotypically and func-
tionally (Figures 3C and 3D). Dectin-1 receptor signaling was
confirmed by blocking of the spleen tyrosine kinase Syk, which
acts downstream of Dectin-1 (Figure 3B). We further used cells
from human genetic Dectin-1 deficiency and used Dectin-1
knockout mice for fungal infection models. The potential of fungi
or fungal patterns to induce neutrophilic MDSCs was diminished
in human and, albeit to a lesser extent, murine Dectin-1 defi-
ciency (Figures 3E and S1D). We analyzed the role of caspase
recruitment domain 9 (CARD9), a downstream adaptor protein
and key transducer of Dectin-1 signaling, in fungi-mediated
MDSC generation in patients with genetic CARD9 deficiency
and Card9 knockout mice. These approaches demonstrated
that CARD9 signaling was involved in fungal MDSC induction
in the human and the murine system (Figures 3E and 3F).
C. albicans induces interleukin-1 beta (IL-1b) in vitro (van de
Veerdonk et al., 2009) and in vivo (Hise et al., 2009), which is crit-
ical for antifungal immunity (Vonk et al., 2006). Recent studies
further provided evidence that IL-1b is involved inMDSC homeo-
stasis (Bruchard et al., 2013). We observed an accumulation of
intracellular IL-1b protein in CD33+ myeloid cells followed by
IL-1b release upon Dectin-1 ligand- and fungal-driven MDSC
induction (Figure 4A). IL-1b protein, in turn, was sufficient to drive
MDSC generation to a comparable extent asC. albicans did (Fig-
ure 4B). Studies in Il1r/ mice, characterized by an increased
susceptibility toC. albicans infection, demonstrated that abroga-
tion of IL-1R signaling decreased MDSC accumulation in vivo
(Figures 4B and S4A), and IL-1R antagonism in patients with
autoinflammatory diseases decreased MDSCs (Figure S4B). As
the inflammasome is the major mechanism driving IL-1b gener-
ation in myeloid cells through caspase activities, we blocked
caspases chemically. We observed that pan-caspase inhibition
largely abolished fungi-induced MDSC generation, which was
not recapitulated by caspase-1 inhibition (Figure 4C). We there-
fore focused on caspase-8, since Dectin-1 activation was shown
to trigger IL-1b processing by a caspase-8-dependent mecha-
nism (Ganesan et al., 2014; Gringhuis et al., 2012). Indeed, fungal
MDSC induction was paralleled by a substantial increase of
caspase-8 activity, and caspase-8 inhibition diminished fungal-
induced IL-1b production (Figure 4C) and the potential of
fungi to induce MDSCs (Figure 4C). Conversely, supplementing
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Figure 1. Fungi Induce Functional MDSCs In Vitro and In Vivo
(A) Fungal morphotypes differentially induce MDSCs.
Left panel: MDSCs were generated by incubating PBMCs (5 3 105/ml) from healthy donors with medium only (negative control), or different morphotypes of
A. fumigatus (conidia, 5 3 105/ml; germ tubes, 1 3 105/ml; hyphae, 1 3 105/ml) or C. albicans (yeasts, 1 3 105/ml; hyphae, 1 3 105/ml). The x-fold induction of
MDSCs compared to control conditions is depicted. *p < 0.05.
Right panel: representative histograms of fungi-induced MDSCs (CD11b+CD33+CD14CD16+CXCR4+).
(B) Fungi-induced MDSCs suppress T cells. The suppressive effects of CD33+-MACS-isolated MDSCs were analyzed on CD4+ and CD8+ T cell proliferation.
MDSCs were generated by incubating PBMCs (53 105/ml) from healthy donors with A. fumigatus germ tubes (13 105/ml) or C. albicans yeasts (13 105/ml) for
6 days. Different MDSC-to-T cell ratios were assessed (1:2, 1:4, 1:6, 1:8, and 1:16). The lower bar graphs represent the proliferation index compared to control
conditions as means ± SEM.
(C) MDSCs in patients with fungal infections.
Left panel: MDSCswere characterized as CD14 cells expressing CD33, CD66b, CD16, CD11b, and CXCR4 in the PBMC fraction. The gray line shows unstained
controls. MDSCs were quantified in peripheral blood from healthy controls, immunosuppressed patients without fungal infections (disease controls, n = 5), or
immunosuppressed patients with invasive fungal infections (invasive A. fumigatus infections, n = 9, and invasive C. albicans infections, n = 6). *p < 0.05.
Right panel: representative CFSE stainings, showing the effect of MDSCs isolated (MACS) from patients with invasive A. fumigatus infections (left) or invasive
C. albicans infections (right) on CD4+ and CD8+ T cell proliferation.
(D) Fungi induce MDSCs in mice in vivo.
Upper left panel: C57/BL6 (n = 3mice per treatment group) or BALB/c (n = 4mice per treatment group) wild-typemice were not infected (white bars) or challenged
intranasally with 1 3 104 (light gray bar) or 1 3 106 (dark gray bar) A. fumigatus conidia for 3 days. On the fourth day, a bronchoalveolar lavage (BAL) was
performed, and CD11b+Ly6G+ MDSCs were quantified by FACS. The x-fold induction of CD11b+Ly6G+ MDSCs in the BAL compared to control non-infected
conditions is depicted. *p < 0.05.
Upper right panel: C57BL/6 mice were not infected (white bars) or injected via the lateral tail vein with 2.5 3 105 (light gray bar) or 5 3 105 (dark gray bar)
blastospores of C. albicans. On the fifth day, mice were sacrificed, and CD11b+Ly6G+ MDSCs in the spleen were quantified by FACS. The x-fold induction of
CD11b+Ly6G+ MDSCs in the spleen compared to control non-infected conditions is depicted. n = 5 mice per treatment group. *p < 0.05.
Lower panel: bonemarrow-isolated murine CD11b+Ly6G+MDSCs were co-cultured for 3 days with T cells (CD4+ splenocytes) at a 1:2 (MDSCs:T cell) ratio. T cell
proliferation was analyzed using the CFSE assay with and without MDSCs.
(E) Adoptive transfer of MDSCs modulates survival in fungal infection. For adoptive transfer experiments, CD11b+Ly6G+ MDSCs were isolated from the bone
marrow of BALB/c mice by MACS and checked for T cell suppression. In (A)–(D) bars represent means ± SEM.
Upper panel: adoptive MDSC transfer was performed by intravenous (i.v.) injection of 53 106MDSCs per animal. Sevenmice receivedMDSCs, while sevenmice
served as non-MDSC control animals. A total of 2 hr after the MDSC transfer, mice were i.v. injected with 13 105 blastospores ofC. albicans. Mice were weighed
daily and monitored for survival and signs of morbidity.
Lower panel: for invasive pulmonary A. fumigatus infection survival studies, mice were immunosuppressed by treatment with cyclophosphamide, and MDSC
transfer was performed by i.v. injection of 43 106 MDSCs per animal. Five mice received MDSCs, while five mice served as non-MDSC control animals. After the
MDSC transfer, mice were challenged intranasally with 2 3 105 A. fumigatus conidia and were monitored for survival.
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IL-1b partially restored the abrogated MDSC generation upon
caspase-8 inhibition (Figure S4C).
ROS are key factors in MDSC homeostasis (Gabrilovich and
Nagaraj, 2009) and act downstream of Dectin-1 (Gross et al.,
2009; Underhill et al., 2005). Therefore, we tested the involve-
ment of ROS for fungal Dectin-1 ligand-induced MDSC genera-
tion using chemical inhibitors and cells from human CGD
patients with ROS deficiency. These studies demonstrated that
ROS contributed substantially to fungal MDSC induction (Fig-
ure 4D). Next, we investigated the interaction between ROS,
caspase-8, and IL-1b and found that ROS inhibition dampened
caspase-8 activity in response to fungi (Figure S4D). IL-1b, in
turn, induced ROS production during MDSC culture, suggesting
a positive feedback loop between caspase-8, IL-1b, and ROS in
MDSC generation (Figures S4E and S4F).
DISCUSSION
While the complete genetic deletion of pro-inflammatory cyto-
kines, particularly TNF-a, IL-1a/b, or IFN-g, increases disease
susceptibility in invasive fungal infections (Lionakis and Netea,
2013; Cheng et al., 2012; Gow et al., 2012; Netea et al., 2008,
2010), excessive inflammation causes collateral damage to the
host (Carvalho et al., 2012; Romani et al., 2008), indicating that
efficient protection against fungi requires a fine-tuned balance
between pro-inflammatory effector and counter-regulatory im-
mune mechanisms. Fungal infection induces an immunosup-
pressive state, and in murine models CD80+ neutrophilic cells
have been shown to be importantly involved in this process
(Mencacci et al., 2002; Romani, 2011; Romani et al., 1997). By
combining human and murine experimental systems, we extend
this concept by providing evidence for an MDSC-mediated
mechanism by which fungi modulate host defense, orchestrated
by Dectin-1/CARD9, ROS, caspase-8, and IL-1b. This effect
seems to be specific for neutrophilic MDSCs, since monocytic
MDSCs were unchanged under our experimental conditions
and were previously found to be downregulated by b-glucans
in tumor-bearing mice (Tian et al., 2013).
C. albicans and A. fumigatus infections differ substantially with
respect to T cell dependency and organ manifestation (Garcia-
Vidal et al., 2013). Our finding that neutrophilic MDSCswere pro-
tective in a murine model of systemic C. albicans infection, but
had no effect on pulmonary A. fumigatus infection, underlines
this disparity and suggests MDSCs as a potential therapeutic
approach in invasive C. albicans, rather than A. fumigatus infec-
tions. The MDSC-mediated effect was associated with down-
regulated NK and T cell activation, and Th17 responses and
supplementing IL-17A in vivo could, at least partially, dampen
the protective effect of MDSCs. Based on previous studies
showing that NK cells drive hyperinflammation in candidiasis in
immunocompetent mice (Quintin et al., 2014) and that IL-17 pro-
motes fungal survival (Zelante et al., 2012), we speculate that
MDSCs in fungal infections could act beneficial for the host
by dampening pathogenic hyperinflammatory NK and Th17 re-
sponses (Romani et al., 2008; Zelante et al., 2007). Accordingly,
enhancing neutrophilic MDSCsmay represent an anti-inflamma-
tory treatment strategy for fungal infections, particularly with
C. albicans.
Recent studies put the gut in the center of immunotolerance.
Dectin-1 was found to control colitis and intestinal Th17 re-
sponses through sensing of the fungal mycobiome (Iliev et al.,
2012). The immunological events downstream of Dectin-1 and
their functional impact on Th17 cells remained elusive. Our re-
sults demonstrate that fungal Dectin-1/CARD9 signaling induces
MDSCs todampenTcell responses andsuggest that the immune
homeostasis in the gut could be modulated by fungal-induced
A
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Figure 2. Antifungal Functions
(A) In vivo.
Left panel: survival in the invasive C. albicans
infection model after adoptive MDSC transfer.
Before adoptive transfer, isolated MDSCs were
pretreated with cytochalasin D (CytD, 1 mg/ml,
green line) or with recombinant mouse IL-17A
protein (5 mg/mouse, red line).
Right panel:C. albicansCFUs in kidneys of BALB/c
mice 5 days after adoptive transfer of MDSCs.
Bars represent means ± SD.
(B) In vitro.
Left panel: 1 3 106 human MDSCs were co-
cultured with 13 105 serum opsonized C. albicans
(10:1 ratio) for 3 hr at 37C in RPMI. Serial dilutions
were performed of the cell suspension, and 100 ml
was plated onto YPD agar plates containing peni-
cillin and streptomycin. Plates were incubated for
24–48 hr at 37C, and CFU were enumerated.
Middle and right panels: phagocytic capacity of
human and murine MDSCs. Middle panel; upper
(purple) FACS plots, isolated human granulocytic
MDSCs (low-density CD66b+CD33+ cells) were co-
cultured with or without GFP-labeled C. albicans
(CA) spores (MOI = 1) in RPMI medium at 37C for
90 min. Lower (red) FACS plots, isolated mouse granulocytic CD11b+Ly6G+ MDSCs were co-cultured with or without GFP-labeled C. albicans spores (MOI = 4)
in RPMI medium at 37C for 90 min. Representative dot blots are shown.
Right panel: GFP expression/fluorescence of MDSCs was analyzed by FACS and is given in the right panel as percentage of GFP+ MDSCs.
510 Cell Host & Microbe 17, 507–514, April 8, 2015 ª2015 The Authors
MDSCs. Beyond fungi, the Dectin-1/CARD9 pathway has been
involved in bacterial and viral infections (Hsu et al., 2007),
suggesting that this mechanism could play a broader role in
balancing inflammation at host-pathogen interfaces.
EXPERIMENTAL PROCEDURES
Fungal Strains and Culture Conditions
A. fumigatus ATCC46645 conidia were incubated in RPMI at RT for 3 hr at
150 rpm to become swollen. Alternatively, conidia were cultured in RPMI over-
night at RT, followed by germination in RPMI either at 37C for 3 hr at 150 rpm
to become germ tubes or at 37C for 17 hr at 150 rpm to become hyphae.
C. albicans SC5314 was grown on SAB agar plates at 25C. One colony
was inoculated and shaken at 200 rpm at 30C in SAB broth overnight. To
generate hyphae, live yeast forms of C. albicans were grown for 6 hr at 37C
in RPMI 1640. Killed yeasts and hyphae were prepared by heat treatment of
the cell suspension at 95C for 45 min or by fixing the cells for 1 hr with 4%
paraformaldehyde followed by extensive washing with PBS to completely
remove the fixing agent. The C. albicans-GFP strain TG6 was pre-cultured at
30C, 200 rpm overnight in YPD medium.
Generation, Isolation, and Characterization of MDSCs
Neutrophilic MDSCs in peripheral blood were quantified based on their lower
density and surface marker profiles as published previously (Rieber et al.,
2013). Human MDSCs were generated in vitro according to a published
protocol (Lechner et al., 2010). Murine MDSCs were characterized by
CD11b, Ly6G, and Ly6C. Flow cytometry was performed on a FACS Calibur
(BD Biosciences). Human and murine MDSCs were isolated using MACS
(MDSC Isolation Kit; Miltenyi Biotec).
T Cell Suppression Assays
T cell suppression assays were performed as described previously (Rieber
et al., 2013) using the CFSE method according to the manufacturer’s protocol
(Invitrogen).
Mouse Infection with A. fumigatus and C. albicans
Invasive C. albicans infection was established by IV injection in immunocom-
petent mice, whereas A. fumigatus infection was established by intranasal
challenge in immunosuppressed mice. CD11b+Ly6G+ and CD11b+Ly6C+
cells in the spleens, BAL, and kidneys were quantified by FACS. For adoptive
transfer experiments, CD11b+Ly6G+ MDSCs were isolated by MACS and
transferred by IV injection of 4 or 5 3 106 MDSCs per animal.
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Figure 3. Fungi Induce MDSCs through a Dectin-1-, Syk-, and CARD9-Mediated Mechanism
(A) Fungal factors mediating MDSC induction are heat resistant. MDSCs were generated by incubating PBMCs (5 3 105/ml) from healthy donors with medium
only (negative control), untreated, or heat-denatured (95C, 30min) supernatants (SNT) ofA. fumigatus germ tubes (4%) for 6 days. The x-fold induction ofMDSCs
compared to control conditions is depicted. *p < 0.05 versus control conditions.
(B) Dectin-1 and Syk are involved in fungal MDSC induction. MDSCs were generated in vitro by incubating isolated PBMCs (5 3 105 cells/ml) with A. fumigatus
germ tubes (1 3 105/ml), hyphae (1 3 105/ml), and C. albicans yeasts (1 3 105/ml) for 6 days. Where indicated, PBMCs were pretreated for 60 min with anti-
Dectin-1 blocking antibody (15 mg/ml), soluble WGP (1 mg/ml), and a Syk inhibitor (100 nM). *p < 0.05 blocking versus unblocked conditions.
(C) Dectin-1/CARD9 ligands mimic fungal MDSC induction. MDSCs were generated in vitro by incubating isolated PBMCs with the Dectin-1/CARD9 ligands
zymosan depleted (10 mg/ml), dispersible WGP (20 mg/ml), or curdlan (10 mg/ml). p < 0.05 versus control conditions.
(D) Dectin-1/CARD9 ligands induce functional MDSCs. The suppressive effects of CD33+-MACS-isolated MDSCs were analyzed on CD4+ and CD8+ T cell
proliferation (CFSE polyclonal proliferation assay). MDSCs were generated by incubating PBMCs (5 3 105/ml) from healthy donors with zymosan depleted
(10 mg/ml) or dispersible WGP (20 mg/ml). MDSC, T cell ratio was 1:6.
(E) Fungal MDSC induction in patients with genetic Dectin-1 or CARD9 deficiency.
Left panel: MDSCswere generated in vitro by incubating isolated PBMCs (53 105 cells/ml) from healthy controls (n = 12), an individual with Dectin-1 deficiency, or
patients with CARD9 deficiency (n = 2) with the Dectin-1/CARD9 ligands zymosan depleted (10 mg/ml) or dispersible WGP (20 mg/ml).
Right panel: MDSCs were generated in vitro by incubating isolated PBMCs (53 105 cells/ml) from healthy controls (n = 12), an individual with genetically proven
Dectin-1 deficiency, or patients with CARD9 deficiency (n = 2) with different fungal morphotypes (1 3 105 cells/ml) for 6 days.
(F) CARD9 is involved in fungi-induced MDSC recruitment in vivo. Card9/ mice and age-matched wild-type mice were challenged intranasally with 1 3 106
A. fumigatus conidia for 3 days. On the fourth day, a BAL was performed, and CD11b+Ly6G+ MDSCs were quantified by flow cytometry. In (B), (C), and (E) bars
represent means ± SEM.
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Figure 4. Fungal MDSC Induction Involves IL-1b, Caspase-8, and ROS
(A) Intracellular accumulation and release of IL-1b.
Left panel: gating strategy for intracellular cytokine staining. IL-1b was analyzed in CD33+ myeloid cells using intracellular cytokine staining and flow cytometry.
Zymosan depleted (20, 100, and 500 mg/ml) and WGP dispersible (20, 100, and 500 mg/ml) were used for 1 hr to stimulate cytokine production.
Middle panel: leukocytes isolated from healthy donors (n = 4) were left untreated (empty circles) or were treated for 1 hr with increasing concentrations of
zymosan, WGP, A. fumigatus germ tubes, or C. albicans yeasts (each at 23 105/ml and 13 106/ml). IL-1b synthesis in CD33+ cells was analyzed by intracellular
cytokine stainings by flow cytometry. *p < 0.05 versus control/untreated conditions.
Right panel: co-culture supernatants were collected after incubating isolated PBMCs (5 3 105 cells/ml) with medium only (white bar), A. fumigatus germ tubes
(1 3 105 cells/ml), or C. albicans yeasts (1 3 105/ml) for 3 days. IL-1b was quantified by ELISA. *p < 0.05 versus medium control conditions.
(B) IL-1b signaling is involved in fungal-induced MDSC generation.
Left panel: MDSCs were generated in vitro by incubating isolated PBMCs (5 3 105 cells/ml) with C. albicans yeasts (1 3 105/ml) or recombinant human IL-1b
protein (0.01 mg/ml) for 6 days. *p < 0.05.
Right panel: MDSCs (CD11b+Ly6G+) were quantified in spleens from Il1r/ and age-matched WT mice 2 days after i.v. infection with 1 3 105 blastospores of
C. albicans. *p < 0.05.
(C) Fungal MDSC generation involves caspase-8. MDSCs were generated in vitro by incubating isolated PBMCs (5 3 105 cells/ml) with C. albicans yeasts
(13 105/ml) for 6 days with or without pretreatment (where indicated) with the pan-caspase inhibitor Z-VAD-FMK (10 mM), the caspase-1 inhibitor Z-WEHD-FMK
(50 mM), or the caspase-8 inhibitor Z-IETD-FMK (50 mM). IL-1b protein levels were quantified in cell culture supernatants by ELISA (note: two values were below
detection limit). Caspase-8 activity was quantified in cell lysates using a luminescent assay. *p < 0.05.
(legend continued on next page)
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Figure	  S1,	  related	  to	  Figure	  1	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A.	  FSC/SSC	  characteris:cs	  of	  fungi-­‐induced	  MDSCs	  in	  vitro	  
MDSCs	   were	   generated	   by	   incuba:ng	   PBMCs	   (5	   x	   105	   /ml)	   from	   healthy	   donors	   with	   medium	   only	   (nega:ve	   control,	  
‘Medium	  control’)	  or	  A.	  fumigatus	  germ	  tubes	  (1	  x	  105	  /ml,	  ‘Fungi-­‐induced	  MDSCs’)	  for	  6	  days.	  Dot	  blots	  show	  representa:ve	  
MDSC	  ga:ngs	  for	  subsequent	  immunophenotyping	  based	  on	  surface	  marker	  expression	  proﬁles	  as	  depicted	  in	  Figure	  1a.	  	  
	  	  
B.	  Aspergillus-­‐	  and	  GM-­‐CSF-­‐induced	  MDSCs	  	  diﬀeren:ally	  aﬀect	  	  Th1/Th17	  and	  Th2	  cytokine	  and	  chemokine	  levels	  	  
IL-­‐2	  and	  OKT-­‐3	  s:mulated	  PBMCs	  were	  cultured	  in	  medium	  alone	  or	  together	  with	  Aspergillus-­‐	  or	  GM-­‐CSF-­‐	  induced	  MDSCs	  
for	  96h.	  Cytokine	  and	  chemokine	  concentra:ons	  in	  culture	  supernatants	  were	  analyzed	  by	  mul:plex	  array	  technology.	  	  	  
	  	  
D.	  MDSC	  induc:on	  in	  Dec5n-­‐1-­‐/-­‐	  mice	  
MDSC	  induc:on	  in	  Dec5n1-­‐/-­‐	  mice:	  Dec5n-­‐1-­‐/-­‐	  mice	  and	  age-­‐matched	  wildtype	  mice	  were	  challenged	  intranasally	  with	  1x106	  
CFU	  A.	  fumigatus	  for	  three	  days.	  On	  the	  fourth	  day,	  a	  bronchoalveolar	  lavage	  was	  performed	  and	  granulocy:c	  (CD11b+Ly6G+)	  
or	  monocy:c	  (CD11b+Ly6C+)	  MDSCs	  were	  quan:ﬁed	  by	  ﬂow	  cytometry.	  
C.	  MDSC	  induc:on	  in	  immunodeﬁcient	  mice	  
MDSC	  induc:on	  in	  immunodeﬁcient	  mice:	  BALB/c	  wildtype	  mice	  were	  immunosuppressed	  with	  cyclophosphamide	  (150	  mg/
kg	  bw	  i.p.)	  and	  not	  infected	  (white	  bars)	  or	  challenged	  intranasally	  with	  1x103	  A.	  fumigatus	  conidia	  (grey	  bar)	  for	  three	  days.	  
On	  the	  fourth	  day,	  CD11b+Ly6G+	  MDSCs	  were	  quan:ﬁed	  in	  lungs	  by	  FACS.	  The	  x-­‐fold	  induc:on	  of	  CD11b+Ly6G+	  MDSCs	  in	  the	  
A.	  fumigatus–infected	  lung	  compared	  to	  control	  non-­‐infected	  condi:ons	  is	  depicted.	  Bars	  represent	  means	  ±	  s.e.m.	  *P<0.05	  	  
E.	  Candida-­‐induced	  neutrophilic	  MDSCs,	  but	  not	  conven:onal	  PMNs,	  suppress	  T-­‐cell	  prolifera:on	  	  
Representa:ve	   CFSE	   stainings,	   showing	   the	   eﬀect	   of	   neutrophilic	  MDSCs	   or	   conven:onal	   autologous	   neutrophils	   (PMNs)	  
isolated	  (MACS)	  from	  pa:ents	  with	  invasive	  C.	  albicans	  infec:ons	  on	  CD4+	  and	  CD8+	  T-­‐cell	  prolifera:on.	  
F.	  Eﬀect	  of	  MDSCs	  on	  inﬂamma:on	  
T-­‐	  and	  NK-­‐cell	  ac:va:on	  was	  quan:ﬁed	  in	  kidneys	  (lei	  bars)	  and	  spleens	  (right	  bars)	  (5	  days	  p.i.)	  in	  the	  invasive	  	  
C.	  albicans	   infec:on	  model	  with	  and	  without	  adop:ve	  MDSC	  transfer.	  T	  and	  NK	  cell	  ac:va:on	  was	  measured	  by	  CD69	  and	  
CD25	  surface	  expression	  on	  CD4+	  T	  cells,	  CD8+	  T	  cells	  and	  on	  CD3-­‐DX5+NKp46+	  NK	  cells.	  T	  cell	  graph	  (lei):	  the	  lei	  bars	  show	  
kidney,	  the	  right	  bars	  spleen.	  NK	  cell	  graph	  (right):	  the	  lei	  bars	  show	  kidney,	  the	  right	  bars	  spleen.	  
	  
G.	   IL-­‐17A	   was	   stained	   intracellularly	   in	   CD4+	   splenocytes	   5	   days	   aier	   adop:ve	  MDSC	   transfer	   by	   ﬂow	   cytometry.	   TNF-­‐α	  
protein	  levels	  were	  quan:ﬁed	  in	  serum	  5	  days	  aier	  adop:ve	  MDSC	  transfer	  by	  Bioplex.	  	  
	  
Figure	  S1.	  Phenotypic	  and	  funcMonal	  MDSC	  characterisMcs	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Figure	  S2,	  	  
related	  to	  Figure	  1	  
A	   B	  
C	   D	  
A.	  The	  suppressive	  eﬀects	  of	  CD33+-­‐MACS-­‐isolated	  MDSCs	  on	  NK	  cells	  were	  analyzed	  by	  measuring	  the	  NK	  cell	  cytotoxicity	  
against	   K562	   tumor	   cell	   line	   (europium	   release	   assay).	   MDSCs	   were	   generated	   by	   incubaLng	   PBMCs	   (5x105/ml)	   from	  
healthy	  donors	  with	  A.	  fumigatus	  germ	  tubes	  (1x105/ml).	  MDSC	  to	  NK	  cell	  raLo	  was	  1:1.	  NK	  (Eﬀector,	  E)	  to	  K562	  (Target,	  T)	  
raLo	  was	  5:1.	  Bars	  represent	  means	  ±	  s.e.m.	  *P<0.05;	  	  
B.	  AcLvated	  NK	  cells	  were	  co-­‐cultured	  with	  puriﬁed	  MDSC	  at	  a	  1:1	  raLo	  for	  16h.	  AYer	  co-­‐culture,	  MDSC	  were	  depleted	  and	  
puriﬁed	  NK	  cells	  were	   incubated	  with	  A.	  fumigatus	  germ	  tubes	  at	  a	  1:1	  raLo	  for	  5h.	  Fungal	  cell	  viability	  was	  determined	  
using	  an	  XTT	  assay.	  *P<0.05	  
C.	  MDSCs	  and	  NK	  cells	  were	  isolated	  from	  healthy	  PBMCs	  by	  magneLc	  bead	  technique.	  NK	  cells	  were	  cultured	  in	  medium	  
alone	  or	  co-­‐cultured	  together	  with	  MDSCs	  in	  a	  raLo	  of	  1:1	  overnight	  analogous	  to	  the	  cytotoxicity	  assays.	  Dead	  cells	  were	  
stained	  with	  propidium	   iodide	   (PI).	  Bar	  graphs	  show	  percentages	  of	  PI	  posiLve	  dead	  NK	  cells	  within	  all	  NK	  cells.	  n.s.	  not	  
signiﬁcant	  
D.	  NK	  cell	  viability	  as	  assessed	  by	  propidium	  iodide	  staining	  for	  NK	  cells	  (CD3-­‐CD56+	  cells)	  in	  1:1	  NK-­‐MDSC	  co-­‐culture	  assays.	  
The	  upper	  panel	  shows	  unstained	  controls	  from	  the	  same	  cells.	  
Figure	  S2:	  Aspergillus-­‐induced	  MDSCs	  decrease	  an;fungal	  NK	  killing	  ac;vity	  
CD33+CD14+	  
Figure	  S3:	  Dec;n-­‐1	  and	  TLR4	  
A.	  Histograms	  show	  representaLve	  examples	  of	  DecLn-­‐1	  surface	  expression	  on	  fungi-­‐induced	  MDSCs	  and	  
CD33+CD14+	  cells.	  	  
Fungi-­‐induced	  
MDSCs	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B.	  MDSCs	  were	  generated	  by	  incubaLng	  PBMCs	  (5x105/ml)	  from	  healthy	  donors	  with	  C.	  albicans	  (yeasts:	  1x105/
ml)	  with	  or	  without	  1h	  pretreatment	  with	  the	  TLR4	  inhibitor	  CLI-­‐095	  (1µM).	  The	  x-­‐fold	  inducLon	  of	  MDSCs	  
compared	  to	  control	  condiLons	  is	  depicted.	  Bars	  represent	  means	  ±	  s.e.m.	  	  
Figure	  S3,	  related	  to	  Figure	  3	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Figure	  S4,	  related	  to	  Figure	  4	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A.	  WT	  and	  Il1r-­‐/-­‐	  mice	  were	  i.v.	  injected	  with	  1×105	  blastospores	  of	  Candida	  albicans	  SC5314	  per	  animal	  in	  100	  µl	  PBS.	  Mice	  were	  
weighed	  daily	  and	  monitored	  for	  survival	  and	  weight	  loss.	  Mice	  with	  a	  weight	  loss	  of	  more	  than	  20%	  or	  with	  serious	  symptoms	  
of	  illness	  were	  euthanized.	  For	  MDSC	  quanLﬁcaLon,	  mice	  were	  sacriﬁced	  and	  CD11b+Ly6G+	  MDSCs	  in	  the	  kidneys	  and	  spleens	  
were	  quanLﬁed	  by	  FACS.	  Bars	  represent	  means	  ±	  s.e.m.	  *P<0.05	  
B.	  MDSCs	  were	  quanLﬁed	  in	  peripheral	  blood	  of	  two	  paLents	  before	  and	  aYer	  systemic	  anL-­‐IL-­‐1	  therapy	  using	  the	  IL1-­‐receptor-­‐
antagonist	  anakinra	  (3	  mg/kg	  bw/d).	  PaLent	  1	  (male,	  2	  years	  of	  age,	  3	  months	  on	  anakinra)	  had	  a	  severe	  chronic	  non-­‐classiﬁed	  
autoinﬂammatory	   disease	   and	   paLent	   2	   (female,	   9	   years	   of	   age,	   4	   days	   on	  anakinra)	   suﬀered	   from	   systemic	   onset	   juvenile	  
idiopathic	  arthriLs	  (soJIA).	  
C.	   MDSCs	   were	   generated	   in	   vitro	   by	   incubaLng	   isolated	   PBMCs	   (5x105	   cells/ml)	   with	   C.	   albicans	   yeasts	   (1x105/ml)	   or	  
recombinant	   human	   IL-­‐1β	   (0.01	   µg/ml)	   for	   6	   days	   with	   or	   without	   pretreatment	   with	   the	   caspase-­‐8	   inhibitor	   Z-­‐IETD-­‐FMK	  
(50μM).	  MDSCs	  were	  quanLﬁed	  using	  ﬂow	  cytometry.	  Bars	  represent	  means.	  *P<0.05	  	  
D.	  MDSCs	  were	  generated	   in	  vitro	  by	   incubaLng	   isolated	  PBMCs	  (5x105	  cells/ml)	  with	  C.	  albicans	  yeasts	  (1x105/ml)	   for	  6	  days	  
with	  or	  without	  pretreatment	  with	  the	  NADPH	  oxidase	  inhibitor	  DPI	  (0.1	  µM).	  Caspase-­‐8	  acLvity	  was	  measured	  by	  a	  luminescent	  
assay	  (Caspase-­‐Glo	  8	  Assay	  from	  Promega,	  USA).	  Bars	  represent	  means.	  *P<0.05	  	  
E.	  PBMCs	  of	  healthy	  donors	  were	  treated	  with	  medium	  only	  (control)	  or	  recombinant	  human	  IL-­‐1β	  (0.1	  µg/ml)	  for	  4	  hours.	  AYer	  
sLmulaLon	   with	   PMA	   (200nM)	   for	   another	   8	  minutes,	   ROS	   producLon	   was	  measured	   by	   DHR	   in	   CD33+	  myeloid	   cells.	   Bars	  
represent	  means.	  *P<0.05	  	  
F.	   Proposed	  model	   of	  MDSC	   generaLon	   in	   invasive	   fungal	   infecLons:	   Fungal	   sensing	   through	   DecLn-­‐1	   triggers	   downstream	  
signaling	   cascades	   involving	   Syk	  and	  CARD9,	   leading	   to	   caspase-­‐8	  acLvaLon.	  Caspase-­‐8	  drives	   interleukin-­‐1	   (IL-­‐1)	  producLon.	  
Released	   IL-­‐1	   binds	   to	   the	   IL-­‐1	   receptor	   (IL-­‐1R)	   and	   enhances	   generaLon	   of	   ROS,	   which	   are	   essenLal	   for	   MDSC	   inducLon.	  
Moreover,	  ROS	  are	   involved	   in	   fungal-­‐driven	  caspase-­‐8	  acLvaLon.	  Generated	  MDSCs	   inhibit	  NK	  and	  T-­‐cell	   responses,	   such	  as	  
Th17	  responses	  that	  amplify	  inﬂammaLon	  and	  may	  also	  directly	  aﬀect	  fungal	  survival.	  	  
Figure	  S4:	  IL-­‐1,	  Caspase-­‐8	  and	  ROS	  
Study	  subjects	  
The	  study	  was	  conducted	  at	  the	  University	  Children’s	  Hospital	  Tübingen	  (Germany).	  Informed	  consent	  was	  obtained	  
from	  all	  subjects	  included	  in	  the	  study	  and	  all	  study	  methods	  were	  approved	  by	  the	  local	  ethics	  commiuee.	  At	  Lme	  
of	  blood	  sampling	  all	  healthy	  subjects	  were	  without	  signs	  of	  infecLon,	  inﬂammaLon,	  or	  respiratory	  symptoms.	  Nine	  
paLents	   with	   invasive	   aspergillosis	   (posiLve	   Aspergillus	   galactomannan	   serum	   test	   and	   clinical	   signs	   of	   invasive	  
aspergillosis)	   and	   six	   paLents	  with	   invasive	  Candida	   bloodstream	   infecLons	  were	   also	   included	   in	   the	   study	   aYer	  
wriuen	   informed	  consent.	  These	  paLents	  acquired	   invasive	   fungal	   infecLon	  during	  oncologic	  chemotherapy,	  aYer	  
hematopoieLc	  stem	  cell	  transplantaLon	  or	  showed	  fungal	  endocardiLs.	  Moreover,	  ﬁve	  immunosuppressed	  paLents	  
aYer	  hematopoieLc	  stem	  cell	  transplantaLon,	  but	  without	  fungal	  infecLons,	  were	  included	  as	  disease	  control	  group.	  
In	   two	   paLents	   with	   autoinﬂammatory	   diseases,	   MDSCs	   were	   quanLﬁed	   in	   peripheral	   blood	   before	   and	   aYer	  
treatment	  with	  the	  IL-­‐1R	  antagonist	  anakinra	  (3mg/kg/d).	  We	  further	  obtained	  blood	  from	  two	  paLents	  with	  CARD9	  
deﬁciency	  and	  a	  medical	  history	  of	  several	   invasive	  fungal	   infecLons.	  The	  CARD9	  mutaLons	  were:	  c.883G>A(hom)	  
and	  c.883C>T(hom),	  both	  resulLng	  in	  a	  premature	  terminaLon	  codon	  (Q295X)	  consistent	  with	  a	  previously	  deﬁned	  
CARD9	   defect	   (Glocker	   et	   al.,	   2009).	   On	   protein	   level	   no	   CARD9	   protein	   could	   be	   detected	   in	   the	   paLent’s	  
neutrophils	   and	  monocytes.	  We	   analyzed	   blood	   from	   a	   healthy	   subject	  with	   a	   homozygous	   DecLn-­‐1	   stop	   codon	  
mutaLon	  (Tyr238X)	  consistent	  with	  a	  previously	  described	  DecLn-­‐1	  deﬁciency	  (Ferwerda	  et	  al.,	  2009).	  This	  mutaLon	  
was	   idenLﬁed	   through	   a	  whole	   exome	   sequencing	   approach	   for	   his	   aﬀected	   daughter.	   In	   addiLon,	  we	   obtained	  
fresh	  blood	  samples	  from	  three	  paLents	  with	  chronic	  granulomatous	  disease	  (CGD)	  and	  complete	  ROS	  deﬁciency.	  
	  
Supplemental	  Experimental	  Procedures	  
A.	  fumigatus	  strain	  and	  culture	  condiLons	  
A.	  fumigatus	  ATCC46645	  conidia	  were	  frozen	  at	  -­‐80°C	  in	  glycerol	  stocks.	  AYer	  growing	  on	  Sab	  agar	  plates	  at	  37°C,	  
one	  colony	  was	  inoculated	  into	  Sab	  broth	  and	  shaken	  at	  37°C	  overnight.	  Conidia	  were	  incubated	  in	  RPMI	  at	  room	  
temperature	  (RT)	  for	  3	  h	  at	  150	  rpm	  to	  become	  swollen.	  AlternaLvely,	  conidia	  were	  cultured	  in	  RPMI	  overnight	  at	  
RT,	  followed	  by	  germinaLon	  in	  RPMI	  either	  at	  37°C	  for	  3	  h	  at	  150	  rpm	  to	  become	  germ	  tubes	  or	  at	  37°C	  for	  17h	  at	  
150	   rpm	   to	  become	  hyphae.	   Fungi	  were	  washed	   twice	   in	   PBS	   and	  heat-­‐inacLvated	   for	   30	  min	   at	   95°C.	   Culture	  
supernatants	   from	  conidia,	  germ	  tubes	  and	  hyphae	  were	  centrifuged	  at	  8000	  rpm	  for	  15	  min,	   followed	  by	  steril	  
ﬁltraLon	  using	  a	  0.2	  µm	  ﬁlter,	  respecLvely.	  	  	  
	  	  	  
C.	  albicans	  strain	  and	  culture	  condiLons	  
C.	  albicans	  SC5314	  was	  stored	  as	  frozen	  stocks	  in	  35	  %	  glycerol	  at	  –80	  °C	  and	  rouLnely	  grown	  on	  Sabouraud	  (Sab)	  
agar	   plates	   at	   25°C.	   	  One	   colony	  was	   inoculated	   and	   shaken	   at	   200	   rpm	   at	   30°C	   in	   Sab	   broth	   (1%	  mycological	  
peptone	   and	   4%	   glucose)	   overnight.	   Cells	   were	   harvested	   by	   centrifugaLon	   and	   washed	   twice	   in	   Dulbecco's	  
phosphate-­‐buﬀered	  saline	  (PBS).	  Cells	  were	  counted	  in	  a	  haemocytometer	  and	  density	  was	  adjusted	  to	  the	  desired	  
concentraLon	  in	  either	  PBS	  or	  RPMI	  1640	  medium.	  To	  generate	  hyphae,	  live	  yeast	  forms	  of	  C.	  albicans	  were	  grown	  
for	  6	  h	  at	  37°C	  in	  RPMI	  1640	  (Gibco-­‐BRL).	  Killed	  yeasts	  and	  hyphae	  were	  prepared	  by	  heat	  treatment	  of	  the	  cell	  
suspension	  at	  95°C	  for	  45	  minutes	  or	  by	  ﬁxing	  the	  cells	  for	  1	  h	  with	  4%	  paraformaldehyde	  followed	  by	  extensive	  
washing	  with	  PBS	  to	  completely	  remove	  the	  ﬁxing	  agent.	  The	  C.	  albicans-­‐GFP	  strain	  TG6	  (a	  generous	  giY	  from	  Dr.	  
Steﬀen	  Rupp,	  Fraunhofer	  IGB	  Stuugart)	  was	  pre-­‐cultured	  at	  30°C,	  200	  rpm	  overnight	   in	  YPD	  medium.	  Cells	  were	  
washed	  twice	  with	  sterile	  PBS	  and	  counted	  using	  a	  haemocytometer	  prior	  to	  use.	  	  
	  
In	  vitro	  generaLon	  and	  isolaLon	  of	  human	  MDSCs	  
Human	  MDSCs	  were	  generated	  in	  vitro	  according	  to	  a	  previously	  published	  protocol	  (Lechner	  et	  al.,	  2010).	  Isolated	  
human	  PBMCs	  were	  cultured	   in	  12	  well	  ﬂat-­‐bouom	  plates	   (Corning)	  or	  25	  cm²	  ﬂasks	   (Greiner	  Bio-­‐One)	  at	  5	  x	  105	  
cells	  /ml	  in	  complete	  medium	  for	  6	  d,	  and	  GM-­‐CSF	  (10	  ng/ml,	  Genzyme),	  heat	  inacLvated	  (95°C,	  30min)	  A.	  fumigatus	  
morphotypes	   (1:1	   to	   1:5	   Aspergillus	   /	   PBMC	   raLo),	   A.	   fumigatus	   lysates	   (Miltenyi	   Biotec),	   A.	   fumigatus	   culture	  
supernatants	   (4%),	   heat	   or	   formaldehyde	   inacLvated	  C.	   albicans	   yeast	   and	   hyphae	   (1:5	   to	   1:20	   Candida	   /	   PBMC	  
raLo),	   curdlan	   (10	   µg/ml,	   Invivogen),	   depleted	   zymosan	   (10	   µg/ml,	   Invivogen)	   and	   WGP	   dispersible	   (20	   µg/ml,	  
Invivogen)	  were	  added	  as	  indicated	  in	  the	  respecLve	  ﬁgures.	  For	  blocking/inhibiLon	  experiments	  mouse	  anL-­‐human	  
DecLn-­‐1	  blocking	  anLbody	  (15	  µg/ml,	  AbD	  Serotec),	  WGP	  soluble	  (1	  mg/ml,	  Invivogen),	  small	  molecule	  syk-­‐inhibitor	  
(100	  nM,	  Calbiochem),	  the	  pan-­‐caspase	  inhibitor	  Z-­‐VAD-­‐FMK	  (10μM,	  R&D	  Systems),	  the	  caspase-­‐8	  inhibitor	  Z-­‐IETD-­‐
FMK	  (50μM,	  R&D	  Systems),	  the	  caspase-­‐1	  inhibitor	  Z-­‐WEHD-­‐FMK	  (50μM,	  R&D	  Systems),	  DPI	  (0.1µM,	  Sigma-­‐Aldrich),	  
Catalase	  (100	  U/l,	  Sigma-­‐Aldrich),	  the	  TLR4	  inhibitor	  CLI-­‐095	  (1µM,	  Invivogen)	  and/or	  cytochalasin	  D	  (2µg/ml;	  Enzo	  
Life	   Sciences)	   were	   added	   as	   indicated	   in	   the	   respecLve	   ﬁgures.	   PBMCs	   cultured	   in	   medium	   alone	   were	   run	   in	  
parallel	  as	  a	  control	  for	  each	  experiment.	  Medium	  and	  supplements	  were	  refreshed	  aYer	  three	  days.	  AYer	  six	  days,	  
all	   cells	   were	   collected	   from	   PBMC	   cultures.	   Adherent	   cells	   were	   removed	   using	   non-­‐protease	   cell	   detachment	  
soluLon	   Detachin	   (GenlanLs).	   MDSCs	   were	   characterized	   as	   CD33+CD11b+CD16+CD14-­‐	   cells	   using	   recently	  
established	  species-­‐speciﬁc	  MDSC	  markers	  (Rieber	  et	  al.,	  2013a;	  Rieber	  et	  al.,	  2013b).	  For	  funcLonal	  studies	  CD33+	  
MDSCs	  were	   isolated	  from	  each	  culture	  using	  anL-­‐CD33	  magneLc	  microbeads	  and	  LS	  column	  separaLon	  (Miltenyi	  
Biotech)	  with	  two	  sequenLal	  separaLon	  steps	  according	  to	  manufacturer’s	  instrucLons.	  	  
	  
Flow	  cytometry	  
Neutrophilic	  MDSCs	  in	  peripheral	  blood	  were	  quanLﬁed	  as	  published	  previously	  by	  our	  group	  (Rieber	  et	  al.,	  2013a).	  
AnLbodies	   against	   human	   CD3,	   CD4,	   CD8,	   CD14,	   CD16,	   CD66b,	   HLA-­‐DR	   and	   CXCR4	   were	   purchased	   from	   BD	  
Pharmingen.	  AnLbodies	  against	  CD11b	  and	  CD33	  were	  purchased	  from	  MiltenyiBiotec.	  AnLbodies	  against	  DecLn-­‐1	  
were	  purchased	   from	  R&D	  Systems.	  Mouse	   IgG1-­‐FITC,	  Mouse	   IgM-­‐FITC,	  Mouse	   IgG1-­‐PE	  and	  Mouse	   IgG1-­‐APC	   (BD	  
Pharmingen)	   were	   used	   as	   isotype	   controls.	   AnLbodies	   against	   mouse	   CD11b,	   Ly6G	   and	   Ly6C	   were	   from	   BD	  
Biosciences,	  anL-­‐mouse	  CXCR4	  was	  from	  Biolegend.	  AnL-­‐mouse	  CD4	  and	  IL-­‐17A	  were	  from	  Miltenyi	  Biotech.	  CD3,	  
CD8,	   CD25,	   CD69,	   NKp46,	   DX5	   and	   the	   corresponding	   isotype	   controls	   were	   from	   Biolegend.	   T	   cells	   were	  
characterized	  by	  CD3,	  CD4,	  CD8,	  CD25	  and	  CD69	  stainings.	  NK	  were	  characterized	  by	  CD3-­‐,	  NKp46,	  DX5	  and	  CD69	  
stainings.	  Where	  indicated,	  T-­‐	  and	  NK-­‐	  cell	  acLvaLon	  in	  mice	  were	  analyzed	  in	  spleen	  and	  kidney	  Lssues.	  Leukocyte	  
enrichment/isolaLon	   from	   kidney	   Lssues	   was	   performed	   as	   described	   previously	   (Lionakis	   et	   al.,	   2011).	   In	   brief,	  
kidneys	  were	  asepLcally	  removed,	  ﬁnely	  minced	  and	  digested	  with	  Liberase	  TL	  and	  DNase	  (Roche)	  for	  30	  min	  with	  
intermiuent	   shaking	   at	   37°C.	   Digested	   Lssue	   was	   passed	   through	   a	   70-­‐µm	   ﬁlter,	   washed	   with	   sterile	   PBS	   and	  
remaining	   red	   cells	   were	   lysed	   with	   lysis	   buﬀer.	   ResulLng	   suspensions	   were	   passed	   through	   a	   40-­‐μm	   ﬁlter	   and	  
washed	   with	   PBS.	   Pellet	   was	   resuspended	   in	   8	   ml	   of	   40%	   Percoll	   (GE	   Healthcare).	   Leukocyte	   enrichment	   was	  
performed	  by	  overlaying	  Percoll-­‐cell	   suspension	  on	  3	  ml	  of	  70%	  Percoll	   soluLon,	  and	  centrifugaLon	  at	  2,000	   rpm	  
without	   brakes	   for	   30	  min	   at	   RT.	   The	   interphase	  was	   collected	   carefully,	  washed	   in	   PBS	   and	   suspended	   in	   FACS	  
buﬀer.	   Cells	   were	   counted	   using	   a	   haematocytometer.	   Flow	   cytometry	   was	   performed	   on	   a	   FACS	   Calibur	   (BD).	  
Results	   were	   expressed	   as	   percent	   of	   posiLve	   cells	   and	   mean	   ﬂuorescence	   intensity	   (MFI).	   CalculaLons	   were	  
performed	  with	  BD	  CellQuestPro	  analysis	  soYware.	  
	  
	  	  
T-­‐cell	  suppression	  assays	  
T-­‐cell	  suppression	  assays	  were	  performed	  as	  described	  previously	  by	  us	  in	  detail	  (Rieber	  et	  al.,	  2013a).	  Responder-­‐PBMCs	  were	  
obtained	   from	   healthy	   volunteers	   and	   stained	   with	   carboxyﬂuoresceinsuccinimidyl	   ester	   (CFSE)	   according	   to	   the	  
manufacturer's	   protocol	   (Invitrogen).	   PBMCs	  were	   sLmulated	  with	  100	  U/ml	   Interleukin-­‐2	   (IL-­‐2;	   R&D	  Systems)	   and	  1	  μg/ml	  
OKT3	   (Janssen	   Cilag).	   In	   a	   standardized	   way,	   60,000	   PBMCs	   per	   well	   in	   RPMI1640	   (Biochrom)	   were	   seeded	   in	   a	   96-­‐well	  
microLtre	   plate	   and	   RPMI1640	   only	   or	   3,750	   (1:16)	   to	   30,000	   (1:2)	  MDSCs	   in	   RPMI1640	  were	   added.	   The	   cell	   culture	  was	  
supplemented	  with	  10%	  heat-­‐inacLvated	  human	  serum,	  2mM	  glutamine,	  100	   IU/ml	  penicillin,	  and	  100	  mg/ml	  streptomycin.	  
AYer	  96h	  of	  incubaLon	  in	  a	  humidiﬁed	  atmosphere	  at	  37°C	  and	  5%	  CO2	  cells	  were	  harvested	  and	  supernatants	  were	  frozen	  in	  
-­‐20°C.	   For	   mouse	   T-­‐cell	   suppression	   assays,	   CD11b+Ly6G+	   MDSCs	   were	   isolated	   from	   bone-­‐marrows	   using	   MACS	   (MDSC	  
isolaLon	  kit,	  Miltenyi	  Biotec,	  Germany)	  and	  were	  co-­‐cultured	  for	  three	  days	  (37°C,	  5%	  CO2)	  with	  T	  cells	  (CD4+	  splenocytes)	  at	  a	  
1:2	  (MDSCs	  :	  T-­‐cell)	  raLo.	  T	  cells	  were	  acLvated	  with	  CD3/CD28-­‐beads	  (mouse	  T	  cell	  acLvaLon	  kit,	  Miltenyi	  Biotec,	  Germany)	  
and	  recombinant	  mouse	  IL-­‐2	  (50	  U/ml,	  Biolegend).	  The	  cell	  culture	  was	  supplemented	  with	  10%	  fetal	  bovine	  serum	  and	  2mM	  
glutamine.	  CFSE-­‐ﬂuorescence	  intensity	  for	  human	  and	  murine	  assays	  was	  analyzed	  by	  ﬂow	  cytometry	  to	  determine	  polyclonal	  
T-­‐	  cell	  proliferaLon.	  
	  	  
Intracellular	  cytokine	  analysis	  
Erythrocytes	  were	  lysed	  with	  Pharm	  Lyse	  Buﬀer	  (BD	  Pharmingen),	  leukocytes	  were	  washed	  with	  cold	  PBS	  and	  resuspended	  in	  
RPMI	  (3	  ml)	  with	  supplements	  (10%	  human	  serum,	  100	  U/ml	  Penicillin,	  100	  U/ml	  Streptomycin,	  2	  mM	  L-­‐glutamine;	  Gibco)	  with	  
the	  addiLon	  of	  benzonase	  (50	  U/ml;	  Promega).	  The	  cells	  were	  plated	  into	  a	  96-­‐well	  ﬂat	  bouom	  plate	  (200	  µl),	  sLmulated	  as	  
indicated	   and	  were	   cultured	   for	   one	   hour	   (37°C;	   5%	  CO2).	   Brefeldin	   A	   (Sigma)	  was	   added	   (cﬁnal	   =	   10	   µg/ml)	   and	   cells	  were	  
cultured	  overnight.	  The	  cells	  were	  harvested	  and	  washed	  with	  cold	  PBS	  (0.1%	  sodium	  azide).	  LIVE⁄DEAD	  Fixable	  Aqua	  was	  used	  
to	   stain	  dead	   cells	   (Life	   Technologies).	   Fc-­‐receptors	  were	  blocked	  with	   Flebogamma	   (50	  µg/ml,	  Grifols	  Biologicals)	   and	   cells	  
were	  stained	  extracellularly	  with	  anL-­‐CD33	  PerCP-­‐Cy5.5	  (BD	  Pharmingen).	  The	  cells	  were	  ﬁxed	  and	  permeabilized	  with	  Cytoﬁx/
Cytoperm	   (BD	   Pharmingen),	   Fc-­‐receptors	   were	   blocked	   as	   before	   and	   IL-­‐1β	   was	   stained	   intracellularly	   (eBioscience).	   Flow	  
cytometry	  was	   performed	   on	   a	   FACS	   Canto	   II	   (BD	   Pharmingen).	   Results	  were	   expressed	   as	   percent	   of	   CD33+IL-­‐1β+	   cells.	   In	  
murine	  infecLons	  models,	  IL-­‐17A	  was	  stained	  intracellularly	  in	  CD4+	  splenocytes	  by	  ﬂow	  cytometry	  as	  described	  previously	  by	  
us	  (Mays	  et	  al.,	  2013).	  CalculaLons	  were	  performed	  with	  FlowJo	  analysis	  soYware	  (Tree	  Star).	  
	  	  
	  	  
Cytokine	  and	  Caspase	  analyses	  
IL-­‐1β	  ELISA	  Kits	  (R&D	  systems)	  were	  used	  to	  quanLfy	  cytokine	  protein	  levels.	  MulLplex	  cytokine	  array	  analyses	  in	  human	  
MDSC	  /	  PBMC	  co-­‐culture	  supernatants	  and	  mouse	  serum	  were	  performed	  using	  human	  and	  mouse	  Bioplex	  protein	  mulL-­‐
array	  systems	  (Bio-­‐Rad).	  Caspase-­‐8	  acLvity	   in	  cell	   lysates	  was	  analysed	  using	  a	   luminescent	  assay	  (Caspase-­‐Glo	  8	  Assay	  
from	  Promega,	  USA).	  Assays	  were	  performed	  according	  to	  the	  manufacturer’s	  recommendaLons.	  
	  
NK	  cell	  cytotoxicity	  assay	  
NK	  cell	   cytotoxicity	  assays	  were	  performed	  as	  described	  previously	  by	  us	   (Rieber	  et	  al.,	  2013b).	   In	  brief,	  NK	  cells	  were	  
separated	  by	  MACS	  and	  co-­‐incubated	  with	  MDSCs	  for	  16h	  in	  a	  1:1	  raLo.	  AYerwards	  cytolyLc	  acLvity	  of	  NK	  cells	  against	  
K562	  tumor	  cell	  line	  was	  tested	  in	  a	  BATDA	  europium	  release.	  E:T	  raLo	  was	  5:1.	  We	  used	  the	  raLos	  of	  NK	  cell	  cytotoxicity	  
in	  the	  presence	  of	  MDSCs	  /	  NK	  cell	  cytotoxicity	  without	  MDSCs	  for	  staLsLcal	  analysis.	  NK	  cell	  cytotoxicity	  without	  MDSCs	  
was	  set	  to	  a	  ﬁxed	  value	  of	  1.	  For	  A.	  fumigatus	  killing,	  NK	  cells	  were	  pre-­‐sLmulated	  with	  1000	  IU	  IL-­‐2	  (MiltenyiBiotec)	  for	  
24h.	  AcLvated	  NK	  cells	  were	  co-­‐cultured	  with	  puriﬁed	  MDSC	  at	  a	  1:1	  raLo	  for	  16h.	  AYer	  co-­‐culture,	  MDSC	  were	  depleted	  
using	  a	  MACS	  separaLon	  column	  (MiltenyiBiotec)	  and	  puriﬁed	  NK	  cells	  were	  incubated	  with	  A.	  fumigatus	  germ	  tubes	  at	  a	  
1:1	  raLo	  for	  5h.	  NK	  cells	  were	  lysed	  using	  ddH2O	  and	  a	  cell	  viability	  assay	  (2,3-­‐Bis-­‐(2-­‐methoxy-­‐4-­‐nitro-­‐5-­‐sulfophenyl)-­‐2H-­‐
tetrazolium-­‐5-­‐carboxanilid	  [XTT]	  assay)	  was	  performed	  to	  determine	  killing	  of	  A.	  fumigatus.	  Propidium	  iodide	  was	  used	  to	  
analyse	  NK	  cell	  death.	  
	  
	  	  
Fungal	  phagocytosis	  and	  killing	  assays	  
MDSCs	   were	   isolated	   by	   MACS	   separaLon	   and	   the	   phagocyte	   killing	   assay	   was	   performed	   as	   described	  
previously	  for	  neutrophils	  (Bambach	  et	  al.,	  2009).	  Brieﬂy,	  1	  ×	  106	  MDSC	  were	  cocultured	  with	  1	  ×	  105	  serum	  
opsonized	  C.	  albicans	  (10:1	  raLo)	  for	  3	  h	  at	  37°C	  in	  RPMI.	  The	  cells	  were	  centrifuged,	  and	  suspended	  in	  sterile	  
water	   for	   lysis.	  Serial	  diluLons	  were	  performed	  of	   the	  cell	   suspension	  and	  100	  μl	  was	  plated	  onto	  YPD	  agar	  
plates	   containing	   penicillin	   and	   streptomycin.	   Plates	   were	   incubated	   for	   24-­‐48	   h	   at	   37°C	   and	   CFUs	   were	  
enumerated.	  The	  phagocyLc	  capacity	  of	  human	  and	  murine	  MDSCs	  was	  further	  assessed	  by	  FACS.	  Therefore,	  
MACS-­‐isolated	   human	   granulocyLc	   MDSCs	   (low	   density	   CD66b+CD33+	   cells)	   were	   co-­‐cultured	   with	   GFP–
labelled	  C.	  albicans	  spores	  (MOI=1)	   in	  RPMI	  medium	  at	  37	  °C	  for	  90	  min.	  MACS-­‐isolated	  mouse	  granulocyLc	  
CD11b+Ly6G+	  MDSCs	  were	  co-­‐cultured	  with	  GFP–labelled	  C.	  albicans	  spores	  (MOI=4)	  in	  RPMI	  medium	  at	  37°C	  	  
for	  90	  minutes.	  GFP	  expression	  of	  MDSCs	  was	  analyzed	  by	  FACS.	  
	  
	  	  
Mouse	  infecLon	  with	  A.	  fumigatus	  and	  C.	  albicans	  	  
All	  animal	  studies	  were	  approved	  by	  the	  local	  authoriLes	  (TVA/RP	  IDs:	  AZ	  35/9185.81-­‐2	  /	  K5/13).	  A.	  fumigatus	  conidia	  (strain	  
ATCC46645)	  were	  harvested	  on	  the	  day	  of	  infecLon,	  submerged	  in	  0.9%	  NaCl	  +	  0.002%	  Tween-­‐20,	  ﬁltered,	  centrifuged	  for	  10	  
min	  3000	  rpm	  and	  resuspended	  in	  5	  mL	  0.9%	  NaCl	  +	  0.002%	  Tween-­‐20.	  Card9-­‐/-­‐	  mice	  on	  a	  C57/BL6	  background,	  Dec@n-­‐1-­‐/-­‐	  
mice	  on	  a	  BALB/c	  background	  or	  age-­‐matched	  C57/BL6	  or	  BALB/c	  WT	  mice,	  respecLvely,	  were	  challenged	  intranasally	  with	  
1x104	  or	  1x106	  A.	   fumigatus	  conidia	   for	   three	  days.	  At	   the	  fourth	  day,	  a	  bronchoalveolar	   lavage	  (BAL)	  was	  performed	  and	  
CD11b+Ly6G+	   and	  CD11b+Ly6C+	   cells	  were	   quanLﬁed	   in	   BAL	   ﬂuid	   by	   FACS.	  C.	   albicans	   (strain	   SC5314)	  was	   grown	   at	   30°C	  
overnight	   in	   liquid	   YPD	   (yeast	   extract,	   peptone,	   and	  dextrose)	  medium	  containing	  penicillin	   and	   streptomycin.	   Cells	  were	  
collected	  by	  centrifugaLon,	  washed	  and	  resuspended	  in	  PBS.	  Required	  cell	  density	  was	  adjusted	  using	  a	  haemocytometer.	  
For	   infecLon,	   female	  C57BL/6	  mice	  were	   injected	  via	  the	   lateral	  tail	  vein	  with	  2.5×105	  or	  5×105	  blastospores	  per	  animal	   in	  
200	  µl	  PBS.	  Control	  animals	  were	  given	  PBS	  only.	  CD11b+Ly6G+	  cells	  in	  the	  spleens	  were	  quanLﬁed	  by	  FACS.	  Where	  indicated,	  
C.	  albicans	  infecLon	  experiments	  (see	  details	  above)	  were	  performed	  in	  Il1r-­‐/-­‐	  on	  a	  C57BL/6	  background	  and	  matched	  C57BL/
6	  WT	  mice.	  For	  adopLve	  transfer	  experiments,	  CD11b+Ly6G+	  MDSCs	  were	  isolated	  from	  the	  bone	  marrow	  of	  healthy	  female	  
BALB/c	  mice	  by	  MACS	  (MDSC	  isolaLon	  kit,	  Miltenyi	  Biotec,	  Germany).	  Transfer	  was	  performed	  by	  injecLng	  4-­‐5×106	  MDSCs	  
per	   animal	   into	   eight	   to	   twelve	  weeks	   old	   (18–22	   g)	   female	  BALB/c	  mice	   via	   lateral	   tail	   vein.	   Two	   hours	   aYer	   the	  MDSC	  
transfer,	  mice	  were	  i.v.	  injected	  with	  1×105	  blastospores	  of	  C.	  albicans	  (SC5314	  in	  100	  µl	  PBS).	  Mice	  were	  weighed	  daily	  and	  
monitored	   for	   survival	   and	   signs	   of	   morbidity.	   Mice	   with	   a	   weight	   loss	   of	   more	   than	   20%	   were	   euthanized.	   For	   CFU	  
determinaLon,	  mice	  were	  euthanized	  at	  day	  5	  post-­‐infecLon.	  The	  kidneys	  were	  asepLcally	   removed,	  homogenized	   in	  1ml	  
PBS,	  serially	  diluted,	  and	  plated	  in	  duplicate	  on	  YPD	  agar	  containing	  penicillin	  and	  streptomycin.	  CFUs	  were	  determined	  aYer	  
48	  hrs	  of	  incubaLon	  at	  37°C.	  To	  assess	  the	  impact	  of	  phagocytosis	  in	  vivo,	  MDSCs	  were	  pretreated	  with	  Cytochalasin	  D	  (1µg/
ml,	   Enzo	   Life	   Sciences)	   prior	   to	   adopLve	   transfer.	   Where	   indicated,	   recombinant	   mouse	   IL-­‐17A	   protein	   (Biolegend)	   was	  
mixed	  with	  C.	  albicans	  suspension	  and	   injected	  via	  mouse	  tail	  vein	  (5µg	  IL-­‐17A	  protein/mouse).	  For	   invasive	  pulmonary	  A.	  
fumigatus	  infecLon	  studies,	  eight	  to	  twelve	  weeks	  old	  (18–22	  g)	  female	  BALB/c	  mice	  were	  immunosuppressed	  by	  treatment	  
with	   cyclophosphamide	   (150	  mg/kg	   bw	   i.p.,	   days	   -­‐3	   and	   -­‐1).	  Mice	   where	   challenged	   intranasally	   with	   1x103	   or	   2x105	  A.	  
fumigatus	   conidia	   (freshly	  harvested	   from	   three	  days	  old	  plates).	   For	   survival	   studies,	  mice	  were	  challenged	  once	  with	  A.	  
fumigatus,	   for	  MDSC	   inducLon	   studies	   for	   three	   consecuLve	   days,	   as	   indicated	   in	   the	   respecLve	   ﬁgure	   legends.	  Where	  
indicated,	  MDSC	   transfer	  was	  performed	  by	   intravenous	   injecLon	  of	  4×106	  MDSCs	  per	  animal	  prior	   to	   infecLon	  and	  mice	  
were	  monitored	  for	  survival	  as	  described	  above.	  
	  
StaLsLcal	  analysis	  
StaLsLcal	  analysis	  was	  done	  using	  GraphPad	  Prism	  5.0	  (Graph	  Pad	  SoYware).	  Diﬀerences	  between	  the	  groups	  
were	  determined	  by	  Students’	  t	  test.	  Survival	  was	  calculated	  using	  the	  Log-­‐rank	  (Mantel-­‐Cox)	  test.	  A	  P	  value	  
of	  <0.05	  was	  considered	  to	  be	  signiﬁcant.	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ABSTRACT Myeloid-derived suppressor cells (MDSCs) are innate immune cells characterised by their
potential to control T-cell responses and to dampen inflammation. While the role of MDSCs in cancer has
been studied in depth, our understanding of their relevance for infectious and inflammatory disease
conditions has just begun to evolve. Recent studies highlight an emerging and complex role for MDSCs in
pulmonary diseases. In this review, we discuss the potential contribution of MDSCs as biomarkers and
therapeutic targets in lung diseases, particularly lung cancer, tuberculosis, chronic obstructive pulmonary
disease, asthma and cystic fibrosis.
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Myeloid-derived suppressor cells
Definition
Suppressive myeloid cells were initially identified more than three decades ago in patients with cancer [1–3].
Later on, these cells were uniformly termed as myeloid-derived suppressor cells (MDSCs) [4] and defined by
1) their myeloid origin and 2) their ability to suppress T-cell responses. Despite a plethora of studies on
MDSCs in mice and men, the precise haematopoietic origin and lineage-association still remain a matter of
debate [5, 6]. Broadly accepted is the notion that MDSCs stem from immature myeloid cells (IMCs) and can
be subdivided into granulocytic/neutrophilic MDSCs (G-MDSCs) and monocytic MDSCs (M-MDSCs).
Current MDSC concepts suggest that differentiation of IMCs into mature granulocytes, macrophages or
dendritic cells (DCs) in bone marrow is skewed towards MDSCs in cancers [7]. While tumour-derived factors,
such as granulocyte/macrophage colony-stimulating factor (GM-CSF), have been proposed to induce MDSCs
in malignancies, the signals that drive MDSC generation in non-malignant infectious and inflammatory
conditions remain incompletely understood [7, 8]. MDSCs are not defined as a single subset of cells, but
rather represent a group of phenotypically heterogeneous myeloid cells that share a common biological
activity. Human MDSCs have been described to commonly express the myeloid markers CD11b and CD33 as
well as CD66b/CD15 for G-MDSCs and CD14 for M-MDSCs [9]. Murine MDSCs express the surface markers
CD11b and Gr1 and lack the expression of cell-surface markers that are specific for macrophages or DCs [10].
Sub-phenotyping divides murine MDSCs into monocytic (Ly-6GlowCD11b+Ly-6ChighSSClow) and
granulocytic/neutrophilic (Ly-6GhighCD11b+Ly-6Cintermed) subsets [7, 11].
Expansion
MDSCs have been reported to expand in malignant, infectious and autoimmune conditions [7, 8]. The
factors driving MDSC expansion comprise a broad variety of pro-inflammatory factors, including
interferon (IFN) γ [12–14], cyclooxygenase (COX) 2, stem-cell factor and prostaglandin E (PGE) [15, 16],
GM-CSF [17], transforming growth factor (TGF) β [18–21], and interleukin (IL) 1β [22]. Signal
transducer and activator of transcription 3 (STAT3) is regarded as the main transcription factor that
regulates the expansion of MDSCs. STAT3 activation increases survival and proliferation of myeloid
progenitor cells and regulates MDSC expansion through inducing the expression of S100A8 and S100A9
proteins [23, 24]. The combination of IL-6 and GM-CSF has been identified to generate MDSCs from
both human and murine immune cells [25, 26]. Beyond GM-CSF and IL-6, microbial factors have been
described to induce MDSCs. Particularly, the opportunistic bacterium Pseudomonas aeruginosa was found
to potently induce MDSC generation through flagellin [27]. Moreover, fungal infections with Aspergillus
fumigatus and Candida albicans induced a distinct subset of MDSCs through the pattern recognition
receptor Dectin-1 and its downstream adaptor protein caspase recruitment domain-containing protein 9,
which further involves the generation of reactive oxygen species (ROS) as well as caspase-8 activity and IL-1
production [28]. The retinoblastoma gene was found to regulate M-MDSC differentiation towards
G-MDSCs in tumour-bearing mice [29]. Under hypoxic conditions in the tumour microenvironment,
MDSCs suppress both antigen-specific and non-specific T-cell activity via hypoxia-inducible factor (HIF)
1α [30]. HIF-1α also redirects MDSCs differentiation toward tumour-associated macrophages, which
further supports the immune-suppressive network in the tumour microenvironment [30]. MDSCs have
been reported to have a shorter lifespan in comparison to their counterparts, granulocytes and monocytes,
in tumour-free mice mediated by tumour necrosis factor (TNF)-related apoptosis–induced ligand receptors
and endoplasmic reticulum stress [31]. LPS and IFN-γ treatment in combination has been shown to trigger
the expansion of splenic myeloid precursors into functionally suppressive MDSCs, blocking their
development into DCs [32]. In addition, it was reported that G-MDSCs are expanded in neonatal cord
blood and efficiently modulate innate and adaptive immune responses by suppressing T and natural killer
(NK) cell responses [33]. These neonatal cord blood MDSCs may weaken cellular anti-microbial host
defence responses and may contribute to the increased lung infection susceptibility in neonates.
Function
The mechanisms listed below have been implicated in MDSC-mediated suppression of T-cell function:
Reactive oxygen species
ROS have been implicated in MDSC-derived T-cell suppression as common mechanism in neoplastic
conditions, inflammation and microbial infections [34]. MDSCs in both tumour-bearing mice and patients
with cancer produce ROS and inhibition of ROS production diminished the suppressive effect of MDSCs
[35–38]. It has been further shown that ligation of integrins, expressed on MDSCs, contribute to increased
ROS production following the interaction of MDSCs with T-cells [39]. Several cytokines, such as TGF-β,
IL-6, and GM-CSF, have been described to induce the production of ROS by MDSCs [40].
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Arginase, nitric oxide synthase and nitric Oxide
Arginase (ARG) 1 and inducible nitric oxide synthase (iNOS) are involved in L-arginine metabolism.
iNOS generates nitric oxide (NO) from L-arginine, and arginase converts L-arginine into urea and
L-ornithine. MDSCs express high levels of arginase and iNOS, and utilise these enzymes to deprive
arginine and, thereby, inhibit T-cell function [41–43]. The shortage of L-arginine inhibits T-cell
proliferation by decreasing T-cellular CD3ζ expression [44] and inhibiting the upregulation of the
cell-cycle regulators cyclin D3 and cyclin-dependent kinase 4 [45]. On the other hand, NO suppresses
T-cell function through inhibition of Janus kinase 3 and STAT5 in T-cells [46], inhibition of MHC class II
expression [47] and the induction of T-cell apoptosis [48].
Peroxynitrite
Peroxynitrite is one of the most powerful oxidants, and is a product of a chemical reaction between NO and
superoxide anion (O2
–). Peroxynitrite induces the nitration and nitrosylation of the amino acids cysteine,
methionine, tryptophan and tyrosine. Increased levels of peroxynitrite are associated with tumour
progression in many types of cancer [49–54], which has been linked with T-cell unresponsiveness.
Induction of regulatory T-cells
MDSCs were found to promote the development of CD4+CD25+FOXP3+ regulatory T-cells (Tregs), an effect
that required the activation of tumour-specific T-cells and the presence of IFN-γ and IL-10 [55, 56].
Subset-specific mechanisms:
The two main subsets of MDSC employ different mechanisms to suppress T-cell proliferation. The
G-MDSC expresses high levels of ROS and low levels of NO, whereas the M-MDSC conversely expresses
low levels of ROS and high levels of NO, while both subsets express arginase [57]. The suppressive activity
of the G-MDSCs was shown to be ARG1-dependent, in contrast to the STAT1- and iNOS-dependent
mechanism of M-MDSCs [58].
Non-T-cell related mechanisms of suppression
While initially described as merely T-cell suppressive, emerging evidence suggests that MDSCs also interact
with and modulate the function of other immune cells, particularly including macrophages [59], NK cells
[60, 61], and Tregs [61]. Moreover, MDSCs, tumour-associated macrophages (TAMs) and DCs have been
reported to interact and to cross-promote their immunosuppressive activities within the tumour
microenvironment [62]. MDSCs in the tumour microenvironment were described to rapidly differentiate
into TAMs through a HIF-1α mediated mechanism [31]. MDSCs, in turn, producing high levels of IL-10,
downregulate macrophage IL-12 production, promote TAMs and macrophage M2 polarisation and facilitate
the development of Tregs [59, 63]. Furthermore, regulatory DCs (regDCs) have been described in cancer
contexts as distinct DC subpopulation, which directly inhibit effector T-cells and indirectly induce or activate
Treg cells and MDSCs [64]. Mechanistically, the immunosuppressive effects of regDCs were found to be
mediated through IL-10, TGF-β, COX-2, iNOS, arginase and indoleamine 2,3-dioxygenase (IDO) [65–67].
MDSC plasticity/fibrocytic MDSCs
Recent studies suggest that Gr1+ myeloid-derived monocytic cells and MDSCs can transdifferentiate into
extracellular matrix (collagen type I)-producing fibrocytes, a mechanism involving CD4+ T-cells, IL-2,
IL-4, IFN-γ and TNF, GM-CSF/G-CSF, Kruppel-like factor 4 and fibroblast-specific protein 1 [68–70].
Fibrocytic MDSCs were found to interact with activated T-cells in a cell contact dependent manner,
resulting in the production of IDO and leading to Treg expansion [69]. Fibrocytes can migrate into the
tumour stroma microenvironment and further differentiate into myofibroblasts and promote
tumorigenesis [71, 72] as well as metastasis [73]. Targeting fibrocytic MDSCs could represent a strategy to
prevent the formation of the pre-metastatic niches and subsequently suppress metastasis formation.
Other mechanisms
Less established mechanisms used by MDSCs to suppress immune responses include: 1) upregulation of
cyclooxygenase 2 and PGE2 [16]; 2) secretion of TGF-β [22]; and 3) sequestering cysteine as well as
limiting the availability of cysteine, which is an essential amino acid for T-cell activation and proliferation
[74]. Several studies demonstrate that the immunosuppressive functions of MDSCs require cell–cell contact,
suggesting that MDSCs act through cell-surface receptors and/or the release of short-lived paracrine
mediators [7]. MDSCs produce the anti-inflammatory cytokine IL-10 and dampen both CD4+ T-cells and
NK cell responses [7, 75, 76], while promoting the expansion of Treg [63] and M2-like macrophages [59].
MDSCs in lung diseases
Some of the different lung diseases in which MDCs play a role and the mechanisms that are used are
shown if figure 1.
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Lung cancer and lung metastasis
T and NK cells are essential for tumour elimination in the lung [77]. Accordingly, factors that regulate their
activity are of high interest for lung cancer treatment strategies. Accumulating evidence suggest that MDSCs
are responsible for inhibiting host T-cell activity against tumour-associated antigens and consequently
impair the effectiveness of anti-cancer immunotherapeutic approaches [78]. MDSCs numbers were found to
be associated inversely with responsiveness to chemotherapy and positively with shorter survival in patients
with lung cancer [79, 80]. Several studies support the concept that MDSCs dampen T-cells in lung cancer
through direct contact and through mechanisms involving a plethora of mediators and mechanisms, such as
iNOS, ARG1, TGF-β, IL-10 and the induction of Tregs [55, 75, 81–86]. MDSCs are recruited to the tumour
site by the CC chemokine ligand (CCL) 2, CXC chemokine ligand (CXCL) 12, and CXCL5 [87]. The
tumour microenvironment stimulates MDSCs to acquire immunosuppressive properties, which are mediated
through STAT1, STAT3, STAT6 and nuclear factor κB transcription factors [7]. Activated MDSCs, in turn,
produce ARG1, iNOS2, IDO, NADPH oxidase and immunosuppressive cytokines that have the potential to
inhibit cytotoxic T lymphocytes, DC, and NK cells as well as expand CD4+CD25+FoxP3+ Tregs [88, 89].
Many tumour types show an organ tropism of metastatic outgrowth, which was first proposed by Stephen
Paget´s seed and soil theory in 1889 [90]. Colon cancer, as an example, induces predominantly metastasis in
the lung. A decade ago KAPLAN et al. [91] first described the concept of the premetastatic niches appearing in
the lung as target organ. Signalling factors and cytokines of the primary tumour, e.g. vascular endothelial
growth factor, placental growth factor , lysyl oxidases, and TNF or TGF-β, lead to the recruitment of
immature bone marrow derived cells, which mainly consist of G-MDSCs, and form pre-metastatic niches in
organs distinct from the location of the primary tumour. Within the pre-metastatic niche the main drivers
for the infiltration of circulating CXC receptor (CXCR) 4+ tumour cells are the remodelling of the
extracellular matrix by matrix metalloproteinase 9 (MMP9), expression of the adhesion molecule fibronectin,
pro-inflammatory S100A8/9 signalling and finally the release of the chemokine stromal cell-derived factor 1,
the agonist for CXCR4 [91]. Also hypoxia of the primary breast tumour accompanied by angiogenesis
signalling promotes the infiltration of G-MDSCs with potent immunosuppression of NK cells [92].
Allergens P. aeruginosa
MDSC MDSC
MDSCMDSC
Th2 Th17Treg Th2
Asthma
COPD
Cystic fibrosis
Tuberculosis
FIGURE 1 The role of myeloid-derived suppressor cells in lung diseases. In response to allergens (asthma),
cigarette smoke (chronic obstructive pulmonary disease (COPD)), P. aeruginosa bacteria (cystic fibrosis) or
Mycobacterium tuberculosis bacteria (tuberculosis), myeloid-derived suppressor cells (MDSCs) accumulate in
the lungs and cooperate with regulatory T-cells (Tregs) to suppress T-helper type 2 (Th2) cells or Th17-driven
inflammation. In tuberculosis, MDSCs phagocytose the mycobacteria and dampen surrounding T-cell
responses, thereby supporting immune-evasion.
4 DOI: 10.1183/13993003.01572-2015
MECHANISMS OF LUNG DISEASE | S. KOLAHIAN ET AL.
Data from animal lung cancer models showed that COX-2 is involved in MDSC regulation through the
production of PGE2 and ARG1 [43]. SRIVASTAVA et al. [93] demonstrated that Snail, an activating
transcription factor in epithelial-mesenchymal transition, induces tumour growth and metastasis by
increasing MDSCs via increasing intracellular expression of ARG1 in murine lung tumour
microenvironment. In other murine models of lung cancer, targeting of MDSCs using antibodies
improved antitumor activity via enhancing effector and memory T-cell responses, as well as NK cell and
antigen-presenting cell activities [94–96]. Peripheral blood MDSCs levels were shown to correlate with a
higher tumour burden and a worse prognosis [97–99]. Several approaches have been pursued to eliminate
MDSCs in cancer, particularly abrogation of MDSCs using all-trans retinoic acid [100, 101], chemotherapy
(gemcitabine, 5-fluoro-uracil) [102, 103], MMP9 inhibition (amino-biphosphonates) [104], MDSC
proliferation inhibitors such as tyrosine kinase inhibitors (sunitinib and sorafinib) [97, 105, 106], MDSC
recruitment inhibitors (CXCR2 antagonists) [109], MDSC function/activation inhibitors such as COX-2
inhibitors [16, 43, 108] and phosphodiesterase-5 inhibitors (sildanefil) [109]. Another novel approach to
abrogate MDSCs, so called “peptibody” treatment showed complete depletion of blood, splenic, and
intratumoural G- and M-MDSCs in tumour bearing mice, without affecting pro-inflammatory immune
cell types [110]. Based on these studies, the translational and therapeutic potential of targeting MDSCs, in
combination with conventional therapies, could be a promising approach for future anti-cancer therapy in
human patients. Overall, the development of novel therapeutic agents that eliminate the activity of MDSCs
in human lung cancer should accelerate our understanding of their biological role within the tumour
microenvironment.
Asthma
CD11b+Gr1intF4/80+MDSC-like cells were found to accumulate in allergic asthma and to suppress lung
DC-mediated reactivation of primed Th2 cells in a toll-like receptor (TLR) 4- and MyD88-dependent
fashion, mediated by IL-10 and ARG1 [75, 111]. It has been further shown that tumour-derived MDSCs
suppress Th2-dominant inflammation in asthmatic mice, reduce recruitment of inflammatory cells and
suppress production of IgE and Th2 cytokines in a TGF-β1 dependent manner [112]. The chemokine
CCL2 was found to recruit MDSCs into lung tissues in airway inflammation [112]. Aspirin treatment
dampened the accumulation of G-MDSCs in the inflamed lung accompanied by increased Th2 airway
responses [113]. It has further been demonstrated that COX and its product, PGE2, play an important role
in the regulation of activation and accumulation of MDSCs through PGE2 and PGE4 receptors [113, 114].
MDSCs and IL-10 levels significantly increased and negatively correlated with IL-12 levels during the onset
of asthma in both human and mice. IL-10 not only suppressed the production of pro-inflammatory factors
by macrophages, but also reduced cytotoxic effects and decreased NO production. Therefore, it is proposed
that MDSCs play a dual role in asthma by upregulating anti-inflammatory IL-10 and downregulating
pro-inflammatory IL-12 [76]. In a different study, MDSCs enhanced mast cell-mediated secretion of several
inflammatory cytokines, including TNF, IL-6, IL-13, macrophage inflammatory protein-1α and monocyte
chemoattractant protein-1. The mutual interaction of MDSCs and mast cells enhanced the activities of each
cell type, resulting in exacerbated inflammation and airway hyperresponsiveness [115]. Three different
populations of CD11b+Ly-6G+ myeloid cells infiltrated the lung in a mouse model of allergic airway
inflammation where they differentially generate the reactive free radicals NO and O2
–. The Ly-6C+Ly-6G−
subset (predominant NO producer) and the Ly-6C+Ly-6G+ subset were found to suppress T-cell
proliferation. In contrast, the O2
.− that generates the Ly-6C−Ly-6G+ subset enhanced T-cell responses [116].
Superoxide-producing myeloid-derived regulatory cells (MDRCs), present in high numbers in the airways
of patients with mild asthma or chronic obstructive pulmonary disease (COPD), but not in healthy
controls, were, on the other hand, found to enhance proliferation of CD4+ T-cells [117].
COPD
NO producing MDRSCs were found in the airways of patients with mild asthma, but not in COPD
patients or healthy control individuals and, were found to suppress activated CD4+ T-cells [117]. Smoking
upregulated and activated circulating MDSCs in COPD patients, but not in smokers with normal lung
function [118]. In COPD patients the MDSC activation was accompanied by down-regulation of the T-cell
receptor ζ chain expression in T-cells [118]. In addition, it has been shown that MDSCs were elevated in
the bone marrow, spleens, and lungs after 4 months of cigarette smoke exposure, while this was paralleled
by decreased pulmonary DCs [119]. However, these phenotypic MDSCs lacked immune suppressive
activity, and thus were not bona fide MDSCs [119]. In a further study, MDSCs were also increased in
patients with COPD and correlated with elevated levels of Tregs, which is in agreement with studies that
suggest reciprocal control of these two cell types [120]. In summary, these studies suggest that the
accumulation of MDSCs in COPD may underlie the blunted immune response observed in COPD.
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Tuberculosis
Development of active tuberculosis (TB) is known to correlate with impaired T-cell responses, but the
underlying immune mechanisms remained incompletely understood [121–125]. Both patients with acute
(household exposure within 3 months) and chronic TB were recently described to show significantly
higher frequencies of MDSCs that inhibited functions of CD4+ and CD8+ T-cells, including T-cell
proliferation, altered T-cell trafficking as well as production of IL-2, IFN-γ and TNF [126]. The frequency
of CD3−CD244high cells with MDSC phenotypes were significantly higher in active TB patients and were
inversely associated with the activation and functionality of CD4+ and CD8+ T-cells [127]. In murine
experimental pulmonary TB, MDSCs readily phagocytosed Mycobacterium tuberculosis, and released both
pro-inflammatory (IL-6, IL-1α) and immunomodulatory (IL-10) cytokines, while retaining their
suppressive capacity [128]. Excessive MDSC accumulation in lungs correlated with elevated surface
expression of IL-4Rα and increased TB lethality, whereas targeted depletion of MDSCs ameliorated disease
in this animal TB model [128]. In summary, these findings indicate that MDSCs accumulate in lungs
during pulmonary TB and play a dual role in host-pathogen interaction: MDSCs phagocytose and harbour
M. tuberculosis bacteria intracellularly, providing a cellular shelter, while simultaneously dampening
surrounding hostile T-cell responses.
Pulmonary hypertension
Pulmonary hypertension is a progressive syndrome with dysregulated inflammatory processes [129].
Immunohistochemical analysis of lung sections from patients with pulmonary hypertension indicated that
immature DCs are present in peribronchovascular regions of vascular remodelling [130]. In a rat model of
monocrotaline-induced pulmonary hypertension, DCs with immature myeloid phenotype were recruited
to remodelled vessels [130]. In addition, monocyte-derived DCs from patients with pulmonary
hypertension were defective in their ability to stimulate T-cells in an allostimulatory mixed-leukocyte
reaction assay. In this respect, abnormalities of T lymphocyte subsets have been documented in patients
with pulmonary hypertension [131, 132]. In pulmonary hypertension patients, circulating activated MDSC
numbers were significantly increased in comparison to control subjects and correlated with increasing
mean pulmonary artery pressure [133]. A direct mechanistic role for MDSCs in pulmonary hypertension
and inflammation-associated vascular remodelling has not yet been defined.
Cystic fibrosis
Cystic fibrosis (CF) patients are impaired in eradicating P. aeruginosa infections and show skewed T-cell
proliferation and immune responses, but the underlying reasons remained poorly understood [134–136].
Recently, it has been shown that G-MDSCs accumulate in CF patients, particularly in patients chronically
infected with P. aeruginosa and correlate with CF lung disease activity [28]. Flagellated P. aeruginosa
induced MDSC generation, corresponding to TLR5 surface expression on G-MDSCs. Moreover, G-MDSCs
in CF patients were further characterised by an upregulation of the chemokine receptor and
HIV-coreceptor CXCR4 on the surface of MDSCs. Functionally, both CF patient-isolated and
flagellin-induced MDSCs suppressed T-cell proliferation and modulated Th17 cells, as key antibacterial
T-cell populations in CF. Percentages of circulating G-MDSCs correlated with pulmonary function in CF
patients chronically infected with P. aeruginosa. MDSCs could, therefore, represent a novel therapeutic
target in CF patients, particularly in patients chronically infected with P. aeruginosa [26].
Pulmonary infection
Efficient innate host defence is crucial for the elimination of invading pulmonary pathogens [137, 138],
but uncontrolled immune activation leads to collateral tissue damage. Neutrophilic cells that are rapidly
recruited to the site of infection produce ROS and proteases to clear infection. However, due to a relatively
short life span, neutrophils rapidly undergo apoptosis, secondary necrosis or neutrophil extracellular trap
formation at the pulmonary site of infection. MDSCs have been described to efficiently efferocytose
apoptotic neutrophils, mediated by IL-10 [139]. Clearance of dead neutrophils by MDSCs may, therefore
help to resolve lung inflammation, preventing lung injury and ultimately restore tissue homeostasis.
Studies in Stat1−/− mice showed that bacterial infection significantly increased pulmonary MDSCs, while
decreasing neutrophils [139]. These observations suggest that increasing MDSCs via STAT1 inhibition in
combination with effective antibiotic therapy may be beneficial in the context of non-resolving bacterial
pneumonia. On the other hand, it has been shown that expansion of MDSCs and absence of invariant NK
T-cells in influenza A infection suppresses influenza-specific immune responses [140]. These paradoxical
effects in viral and bacterial infection may be due to different MDSC kinetics and/or downstream
responses [139, 140]. MDSCs accumulate in the lungs during pneumocystis pneumonia (PCP) [141].
At the pulmonary site, MDSCs interact with alveolar macrophages through programmed cell death protein
1 and programmed death-ligand 1, leading to macrophage suppression through histone modification and
DNA methylation of the PU.1 gene, finally resulting in PU.1 downregulation. MDSCs employ the same
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mechanism to interact with monocytes, leading to PU.1 downregulation and inhibition of their
differentiation into alveolar macrophages, resulting in decreased numbers and activity of alveolar
macrophages during PCP [142].
Pulmonary inflammation
Exposure of mice to lipopolysaccharide (LPS) triggers the recruitment of a MDSC-like phenotype
(CD11b+Ly6GintLy6Clow/−F4/80+CD80+) into the lung [139], where they reside, in contrast to DCs, which
traffic readily to the lymph nodes [75]. LPS-induced lung MDSCs were further shown to blunt the ability
of pulmonary DCs to promote Th2 responses [75, 143–145]. It is speculated that lung MDSCs
compromise Th2 cell survival, thereby reducing the size of the memory T-cell pool [75, 146, 147]. Thus,
collectively, it appears that an important effector function of TLR-induced MDSCs is not directed to the
lymph node to influence the development of adaptive immune functions, but rather to control local
pulmonary immune responses. Recent studies further suggest that TLR4 activation by LPS induces
GM-CSF and IL-6 production leading to STAT5 and STAT3 activation, which in turn drives MDSC
generation [82, 139, 148, 149]. At the cellular level, MDSCs induce Tregs [150] by increasing Foxp3
expression through an IL-10-, TGF-β- and ARG1-dependent mechanism [150]. It has been further shown
that glucocorticoids induce a distinct anti-inflammatory phenotype in mouse monocytes, which
phenotypically resemble MDSCs with respect to the expression of CD11b, Ly-6G and IL-4Rα chain [151].
Conclusions and outlook
Emerging evidence suggests that MDSCs, as immuosuppressive myeloid cells, play a critical role in
malignant, infectious and inflammatory lung diseases, particularly lung cancer, TB, COPD, pulmonary
hypertension, asthma and CF. Amongst the MDSC subsets, granulocytic MDSCs appear to represent the
major population accumulating in pulmonary diseases. Pathways orchestrating MDSC generation,
recruitment, activation and suppressive functions are diverse and future studies are required to narrow
down the most relevant ones for therapeutic targeting approaches. Mechanistically, a more precise
understanding of how host- or pathogen-derived cues modulate MDSC generation and function will help to
develop tailored MDSC inhibitors for conditions where MDSC cause harm to the host, such as lung cancer
and pulmonary infection (for instance TB), where pulmonary MDSCs favour the survival of malignant cells
or pathogens. Conversely, adoptive cellular transfer or specific activation of MDSCs may represent an
attractive therapeutic strategy to dampen immune responses in the setting of immune over activation, as
found in allergic, autoimmune and auto-inflammatory pulmonary disease conditions. Findings from both
mouse models and human patients indicate a potential therapeutic role for vitamin A and D, tyrosine
kinase inhibitors, chemokine receptor antagonists, COX inhibitors and phosphodiesterase-5 inhibitors in
regulating MDSCs. Clinical interventional studies are the next consequent step to systematically assess the
safety and efficacy of these MDSC-interfering approaches in pulmonary diseases.
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